# PeptideScanner evidence objects: Goserelin

Every published version of the records placed with Goserelin, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/goserelin.json. Selected public evidence only; not medical advice.

- Objects: 63
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct00004124-goserelin-v1"></a>

## ClinicalTrials.gov record NCT00004124

> PeptideScanner retained ClinicalTrials.gov record NCT00004124 at 2026-11-15T21:50:32.222Z. Its registry update date was 2022-12-30, and PeptideScanner's reviewed identity mapping was goserelin.

- Evidence object: `story:clinicaltrials-gov-nct00004124-goserelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-12-30
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00004124-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct00004124-goserelin-v1
- Content SHA-256: `2df134481b5995d7829852c66abafcef238c2fb63eca7a270f580db421527294`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00004124 ([`ctg-observation-nct00004124-2022-12-30-25084de23323`](#source-ctg-observation-nct00004124-2022-12-30-25084de23323))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00004124 at 2026-11-15T21:50:32.222Z. Its registry update date was 2022-12-30, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct00004124-2022-12-30-25084de23323`](#source-ctg-observation-nct00004124-2022-12-30-25084de23323))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00004124 at 2026-11-15T21:50:32.222Z. Its registry update date was 2022-12-30, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct00004124-2022-12-30-25084de23323`](#source-ctg-observation-nct00004124-2022-12-30-25084de23323))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00004124-2022-12-30-25084de23323`](#source-ctg-observation-nct00004124-2022-12-30-25084de23323))

### Sources

<a id="source-ctg-observation-nct00004124-2022-12-30-25084de23323"></a>
- **ClinicalTrials.gov record NCT00004124 · retained source version 2022-12-30:25084de2332371114bb4aad1b1d002436979103be3201c9e13baf20192e1e01e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00004124) (`ctg-observation-nct00004124-2022-12-30-25084de23323`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00004124." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct00004124-goserelin-v1 SHA-256: 2df134481b5995d7829852c66abafcef238c2fb63eca7a270f580db421527294.

---

<a id="clinicaltrials-gov-nct00005044-goserelin-v1"></a>

## ClinicalTrials.gov record NCT00005044

> PeptideScanner retained ClinicalTrials.gov record NCT00005044 at 2026-11-15T21:50:32.222Z. Its registry update date was 2022-06-15, and PeptideScanner's reviewed identity mapping was goserelin.

- Evidence object: `story:clinicaltrials-gov-nct00005044-goserelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-06-15
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00005044-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct00005044-goserelin-v1
- Content SHA-256: `6d435fccad8634c93d13a7ed1abd1fe76606a0ae0d01b34a03ce536c234e88d5`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00005044 ([`ctg-observation-nct00005044-2022-06-15-056230aae193`](#source-ctg-observation-nct00005044-2022-06-15-056230aae193))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00005044 at 2026-11-15T21:50:32.222Z. Its registry update date was 2022-06-15, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct00005044-2022-06-15-056230aae193`](#source-ctg-observation-nct00005044-2022-06-15-056230aae193))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00005044 at 2026-11-15T21:50:32.222Z. Its registry update date was 2022-06-15, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct00005044-2022-06-15-056230aae193`](#source-ctg-observation-nct00005044-2022-06-15-056230aae193))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00005044-2022-06-15-056230aae193`](#source-ctg-observation-nct00005044-2022-06-15-056230aae193))

### Sources

<a id="source-ctg-observation-nct00005044-2022-06-15-056230aae193"></a>
- **ClinicalTrials.gov record NCT00005044 · retained source version 2022-06-15:056230aae1938e1d807e42715cd9e9e8f54b97e2c30dc8f0262ce561f5eebc4b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00005044) (`ctg-observation-nct00005044-2022-06-15-056230aae193`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00005044." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct00005044-goserelin-v1 SHA-256: 6d435fccad8634c93d13a7ed1abd1fe76606a0ae0d01b34a03ce536c234e88d5.

---

<a id="clinicaltrials-gov-nct00108732-goserelin-v1"></a>

## ClinicalTrials.gov record NCT00108732

> PeptideScanner retained ClinicalTrials.gov record NCT00108732 at 2026-11-15T21:50:32.222Z. Its registry update date was 2015-06-30, and PeptideScanner's reviewed identity mapping was goserelin.

- Evidence object: `story:clinicaltrials-gov-nct00108732-goserelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-06-30
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00108732-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct00108732-goserelin-v1
- Content SHA-256: `9a22ba2bade85179efba33e4cf5e66ff69c973dee442fbcf916f231e9a7e62dd`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00108732 ([`ctg-observation-nct00108732-2015-06-30-d8d66e6c18b4`](#source-ctg-observation-nct00108732-2015-06-30-d8d66e6c18b4))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00108732 at 2026-11-15T21:50:32.222Z. Its registry update date was 2015-06-30, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct00108732-2015-06-30-d8d66e6c18b4`](#source-ctg-observation-nct00108732-2015-06-30-d8d66e6c18b4))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00108732 at 2026-11-15T21:50:32.222Z. Its registry update date was 2015-06-30, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct00108732-2015-06-30-d8d66e6c18b4`](#source-ctg-observation-nct00108732-2015-06-30-d8d66e6c18b4))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00108732-2015-06-30-d8d66e6c18b4`](#source-ctg-observation-nct00108732-2015-06-30-d8d66e6c18b4))

### Sources

<a id="source-ctg-observation-nct00108732-2015-06-30-d8d66e6c18b4"></a>
- **ClinicalTrials.gov record NCT00108732 · retained source version 2015-06-30:d8d66e6c18b4961b55bd6b9728dfc013335afb7203907f723b1a3b5e9efd59a5** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00108732) (`ctg-observation-nct00108732-2015-06-30-d8d66e6c18b4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00108732." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct00108732-goserelin-v1 SHA-256: 9a22ba2bade85179efba33e4cf5e66ff69c973dee442fbcf916f231e9a7e62dd.

---

<a id="clinicaltrials-gov-nct00114114-goserelin-v1"></a>

## ClinicalTrials.gov record NCT00114114

> PeptideScanner retained ClinicalTrials.gov record NCT00114114 at 2026-11-15T21:50:32.222Z. Its registry update date was 2019-10-08, and PeptideScanner's reviewed identity mapping was goserelin.

- Evidence object: `story:clinicaltrials-gov-nct00114114-goserelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-10-08
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00114114-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct00114114-goserelin-v1
- Content SHA-256: `dd30d233796ce108c6d98265010fc0e6addd7ee957260740e93d3f95fcc9aba2`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00114114 ([`ctg-observation-nct00114114-2019-10-08-f10a1ebd339d`](#source-ctg-observation-nct00114114-2019-10-08-f10a1ebd339d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00114114 at 2026-11-15T21:50:32.222Z. Its registry update date was 2019-10-08, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct00114114-2019-10-08-f10a1ebd339d`](#source-ctg-observation-nct00114114-2019-10-08-f10a1ebd339d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00114114 at 2026-11-15T21:50:32.222Z. Its registry update date was 2019-10-08, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct00114114-2019-10-08-f10a1ebd339d`](#source-ctg-observation-nct00114114-2019-10-08-f10a1ebd339d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00114114-2019-10-08-f10a1ebd339d`](#source-ctg-observation-nct00114114-2019-10-08-f10a1ebd339d))

### Sources

<a id="source-ctg-observation-nct00114114-2019-10-08-f10a1ebd339d"></a>
- **ClinicalTrials.gov record NCT00114114 · retained source version 2019-10-08:f10a1ebd339d9bb5c16ab5210c3464b37a325724667e2c258e1c9ee73528ae1c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00114114) (`ctg-observation-nct00114114-2019-10-08-f10a1ebd339d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00114114." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct00114114-goserelin-v1 SHA-256: dd30d233796ce108c6d98265010fc0e6addd7ee957260740e93d3f95fcc9aba2.

---

<a id="clinicaltrials-gov-nct00186121-goserelin-v1"></a>

## ClinicalTrials.gov record NCT00186121

> PeptideScanner retained ClinicalTrials.gov record NCT00186121 at 2026-11-15T21:50:32.222Z. Its registry update date was 2019-10-07, and PeptideScanner's reviewed identity mapping was goserelin.

- Evidence object: `story:clinicaltrials-gov-nct00186121-goserelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-10-07
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00186121-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct00186121-goserelin-v1
- Content SHA-256: `4b7e9cf1b523d15035f33fafda0c88536ee005c00b3b630162012b0619812c9a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00186121 ([`ctg-observation-nct00186121-2019-10-07-4de082fb1f6e`](#source-ctg-observation-nct00186121-2019-10-07-4de082fb1f6e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00186121 at 2026-11-15T21:50:32.222Z. Its registry update date was 2019-10-07, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct00186121-2019-10-07-4de082fb1f6e`](#source-ctg-observation-nct00186121-2019-10-07-4de082fb1f6e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00186121 at 2026-11-15T21:50:32.222Z. Its registry update date was 2019-10-07, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct00186121-2019-10-07-4de082fb1f6e`](#source-ctg-observation-nct00186121-2019-10-07-4de082fb1f6e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00186121-2019-10-07-4de082fb1f6e`](#source-ctg-observation-nct00186121-2019-10-07-4de082fb1f6e))

### Sources

<a id="source-ctg-observation-nct00186121-2019-10-07-4de082fb1f6e"></a>
- **ClinicalTrials.gov record NCT00186121 · retained source version 2019-10-07:4de082fb1f6e0677867d84ab449e67b73feef61dee04440884c85efe72f90512** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00186121) (`ctg-observation-nct00186121-2019-10-07-4de082fb1f6e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00186121." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct00186121-goserelin-v1 SHA-256: 4b7e9cf1b523d15035f33fafda0c88536ee005c00b3b630162012b0619812c9a.

---

<a id="clinicaltrials-gov-nct00283803-goserelin-v1"></a>

## ClinicalTrials.gov record NCT00283803

> PeptideScanner retained ClinicalTrials.gov record NCT00283803 at 2026-11-15T21:50:32.222Z. Its registry update date was 2018-08-07, and PeptideScanner's reviewed identity mapping was goserelin.

- Evidence object: `story:clinicaltrials-gov-nct00283803-goserelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-08-07
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00283803-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct00283803-goserelin-v1
- Content SHA-256: `e829bf72951ae71919e4c922a70cd95db26a27ccb886e7ca1ca23fe3b37d5c29`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00283803 ([`ctg-observation-nct00283803-2018-08-07-978f22a7e286`](#source-ctg-observation-nct00283803-2018-08-07-978f22a7e286))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00283803 at 2026-11-15T21:50:32.222Z. Its registry update date was 2018-08-07, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct00283803-2018-08-07-978f22a7e286`](#source-ctg-observation-nct00283803-2018-08-07-978f22a7e286))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00283803 at 2026-11-15T21:50:32.222Z. Its registry update date was 2018-08-07, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct00283803-2018-08-07-978f22a7e286`](#source-ctg-observation-nct00283803-2018-08-07-978f22a7e286))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00283803-2018-08-07-978f22a7e286`](#source-ctg-observation-nct00283803-2018-08-07-978f22a7e286))

### Sources

<a id="source-ctg-observation-nct00283803-2018-08-07-978f22a7e286"></a>
- **ClinicalTrials.gov record NCT00283803 · retained source version 2018-08-07:978f22a7e28655a2d40fde4d42e2d3c512c6921e8ab38b0a0a40ba4fa5b49464** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00283803) (`ctg-observation-nct00283803-2018-08-07-978f22a7e286`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00283803." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct00283803-goserelin-v1 SHA-256: e829bf72951ae71919e4c922a70cd95db26a27ccb886e7ca1ca23fe3b37d5c29.

---

<a id="clinicaltrials-gov-nct00295646-goserelin-v1"></a>

## ClinicalTrials.gov record NCT00295646

> PeptideScanner retained ClinicalTrials.gov record NCT00295646 at 2026-11-15T21:50:32.222Z. Its registry update date was 2024-03-15, and PeptideScanner's reviewed identity mapping was goserelin.

- Evidence object: `story:clinicaltrials-gov-nct00295646-goserelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-03-15
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00295646-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct00295646-goserelin-v1
- Content SHA-256: `c2c4355069e7e7cf89720d59f95e3ef36495981926587a3a85f553580612d1a7`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00295646 ([`ctg-observation-nct00295646-2024-03-15-3335cd368629`](#source-ctg-observation-nct00295646-2024-03-15-3335cd368629))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00295646 at 2026-11-15T21:50:32.222Z. Its registry update date was 2024-03-15, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct00295646-2024-03-15-3335cd368629`](#source-ctg-observation-nct00295646-2024-03-15-3335cd368629))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00295646 at 2026-11-15T21:50:32.222Z. Its registry update date was 2024-03-15, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct00295646-2024-03-15-3335cd368629`](#source-ctg-observation-nct00295646-2024-03-15-3335cd368629))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00295646-2024-03-15-3335cd368629`](#source-ctg-observation-nct00295646-2024-03-15-3335cd368629))

### Sources

<a id="source-ctg-observation-nct00295646-2024-03-15-3335cd368629"></a>
- **ClinicalTrials.gov record NCT00295646 · retained source version 2024-03-15:3335cd36862904ddb24918c6d715e72234543913a2b6387d9de8294f99e3cf75** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00295646) (`ctg-observation-nct00295646-2024-03-15-3335cd368629`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00295646." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct00295646-goserelin-v1 SHA-256: c2c4355069e7e7cf89720d59f95e3ef36495981926587a3a85f553580612d1a7.

---

<a id="clinicaltrials-gov-nct00322348-goserelin-v1"></a>

## ClinicalTrials.gov record NCT00322348

> PeptideScanner retained ClinicalTrials.gov record NCT00322348 at 2026-11-15T21:50:32.222Z. Its registry update date was 2011-01-24, and PeptideScanner's reviewed identity mapping was goserelin.

- Evidence object: `story:clinicaltrials-gov-nct00322348-goserelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2011-01-24
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00322348-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct00322348-goserelin-v1
- Content SHA-256: `f149d733b96fd37d43b1d6c19d4e8a36aedf0eee9fab5f1339eab481af53d52f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00322348 ([`ctg-observation-nct00322348-2011-01-24-939fb5f132f9`](#source-ctg-observation-nct00322348-2011-01-24-939fb5f132f9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00322348 at 2026-11-15T21:50:32.222Z. Its registry update date was 2011-01-24, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct00322348-2011-01-24-939fb5f132f9`](#source-ctg-observation-nct00322348-2011-01-24-939fb5f132f9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00322348 at 2026-11-15T21:50:32.222Z. Its registry update date was 2011-01-24, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct00322348-2011-01-24-939fb5f132f9`](#source-ctg-observation-nct00322348-2011-01-24-939fb5f132f9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00322348-2011-01-24-939fb5f132f9`](#source-ctg-observation-nct00322348-2011-01-24-939fb5f132f9))

### Sources

<a id="source-ctg-observation-nct00322348-2011-01-24-939fb5f132f9"></a>
- **ClinicalTrials.gov record NCT00322348 · retained source version 2011-01-24:939fb5f132f9ae050f562e4d96a2758d32e66215c55602326436f0a6e53193fd** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00322348) (`ctg-observation-nct00322348-2011-01-24-939fb5f132f9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00322348." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct00322348-goserelin-v1 SHA-256: f149d733b96fd37d43b1d6c19d4e8a36aedf0eee9fab5f1339eab481af53d52f.

---

<a id="clinicaltrials-gov-nct00328614-goserelin-v1"></a>

## ClinicalTrials.gov record NCT00328614

> PeptideScanner retained ClinicalTrials.gov record NCT00328614 at 2026-11-15T21:50:32.222Z. Its registry update date was 2025-05-16, and PeptideScanner's reviewed identity mapping was goserelin.

- Evidence object: `story:clinicaltrials-gov-nct00328614-goserelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-05-16
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00328614-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct00328614-goserelin-v1
- Content SHA-256: `e245c7060634a89fed92896af6a2a2f5e48a0d827c442a47e8100b8ea9b68045`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00328614 ([`ctg-observation-nct00328614-2025-05-16-3011f7ddf9f3`](#source-ctg-observation-nct00328614-2025-05-16-3011f7ddf9f3))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00328614 at 2026-11-15T21:50:32.222Z. Its registry update date was 2025-05-16, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct00328614-2025-05-16-3011f7ddf9f3`](#source-ctg-observation-nct00328614-2025-05-16-3011f7ddf9f3))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00328614 at 2026-11-15T21:50:32.222Z. Its registry update date was 2025-05-16, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct00328614-2025-05-16-3011f7ddf9f3`](#source-ctg-observation-nct00328614-2025-05-16-3011f7ddf9f3))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00328614-2025-05-16-3011f7ddf9f3`](#source-ctg-observation-nct00328614-2025-05-16-3011f7ddf9f3))

### Sources

<a id="source-ctg-observation-nct00328614-2025-05-16-3011f7ddf9f3"></a>
- **ClinicalTrials.gov record NCT00328614 · retained source version 2025-05-16:3011f7ddf9f377b41d071ef2256410f6eaef37ae8ae6ef76aa3c18a0e20df29d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00328614) (`ctg-observation-nct00328614-2025-05-16-3011f7ddf9f3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00328614." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct00328614-goserelin-v1 SHA-256: e245c7060634a89fed92896af6a2a2f5e48a0d827c442a47e8100b8ea9b68045.

---

<a id="clinicaltrials-gov-nct00432172-goserelin-v1"></a>

## ClinicalTrials.gov record NCT00432172

> PeptideScanner retained ClinicalTrials.gov record NCT00432172 at 2026-11-15T21:50:32.222Z. Its registry update date was 2023-04-03, and PeptideScanner's reviewed identity mapping was goserelin.

- Evidence object: `story:clinicaltrials-gov-nct00432172-goserelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-04-03
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00432172-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct00432172-goserelin-v1
- Content SHA-256: `8659fc65eff18c0dd8e86ea2b536af2ec776ef4022622eb191f81ba41ac04ea8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00432172 ([`ctg-observation-nct00432172-2023-04-03-3fd0488e5467`](#source-ctg-observation-nct00432172-2023-04-03-3fd0488e5467))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00432172 at 2026-11-15T21:50:32.222Z. Its registry update date was 2023-04-03, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct00432172-2023-04-03-3fd0488e5467`](#source-ctg-observation-nct00432172-2023-04-03-3fd0488e5467))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00432172 at 2026-11-15T21:50:32.222Z. Its registry update date was 2023-04-03, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct00432172-2023-04-03-3fd0488e5467`](#source-ctg-observation-nct00432172-2023-04-03-3fd0488e5467))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00432172-2023-04-03-3fd0488e5467`](#source-ctg-observation-nct00432172-2023-04-03-3fd0488e5467))

### Sources

<a id="source-ctg-observation-nct00432172-2023-04-03-3fd0488e5467"></a>
- **ClinicalTrials.gov record NCT00432172 · retained source version 2023-04-03:3fd0488e546797d51e18ea7f2c71d1e464a86443a93b17a3b9fd50131f955e5c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00432172) (`ctg-observation-nct00432172-2023-04-03-3fd0488e5467`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00432172." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct00432172-goserelin-v1 SHA-256: 8659fc65eff18c0dd8e86ea2b536af2ec776ef4022622eb191f81ba41ac04ea8.

---

<a id="clinicaltrials-gov-nct00586898-goserelin-v1"></a>

## ClinicalTrials.gov record NCT00586898

> PeptideScanner retained ClinicalTrials.gov record NCT00586898 at 2026-11-15T21:50:32.222Z. Its registry update date was 2016-03-25, and PeptideScanner's reviewed identity mapping was goserelin.

- Evidence object: `story:clinicaltrials-gov-nct00586898-goserelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-03-25
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00586898-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct00586898-goserelin-v1
- Content SHA-256: `d9267fc61cb3cb74c4f89d4d1739c43a3d01e36efd8ecaad801215643d1da94f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00586898 ([`ctg-observation-nct00586898-2016-03-25-b5b0f194f1cc`](#source-ctg-observation-nct00586898-2016-03-25-b5b0f194f1cc))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00586898 at 2026-11-15T21:50:32.222Z. Its registry update date was 2016-03-25, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct00586898-2016-03-25-b5b0f194f1cc`](#source-ctg-observation-nct00586898-2016-03-25-b5b0f194f1cc))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00586898 at 2026-11-15T21:50:32.222Z. Its registry update date was 2016-03-25, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct00586898-2016-03-25-b5b0f194f1cc`](#source-ctg-observation-nct00586898-2016-03-25-b5b0f194f1cc))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00586898-2016-03-25-b5b0f194f1cc`](#source-ctg-observation-nct00586898-2016-03-25-b5b0f194f1cc))

### Sources

<a id="source-ctg-observation-nct00586898-2016-03-25-b5b0f194f1cc"></a>
- **ClinicalTrials.gov record NCT00586898 · retained source version 2016-03-25:b5b0f194f1ccc9762c0e545cc7eb3d253db2da5c5f73a44df43bdee51eecbc54** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00586898) (`ctg-observation-nct00586898-2016-03-25-b5b0f194f1cc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00586898." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct00586898-goserelin-v1 SHA-256: d9267fc61cb3cb74c4f89d4d1739c43a3d01e36efd8ecaad801215643d1da94f.

---

<a id="clinicaltrials-gov-nct00605267-goserelin-v1"></a>

## ClinicalTrials.gov record NCT00605267

> PeptideScanner retained ClinicalTrials.gov record NCT00605267 at 2026-11-15T21:50:32.222Z. Its registry update date was 2012-09-06, and PeptideScanner's reviewed identity mapping was goserelin.

- Evidence object: `story:clinicaltrials-gov-nct00605267-goserelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2012-09-06
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00605267-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct00605267-goserelin-v1
- Content SHA-256: `f713ffbdf1a1dc3d9bbc32b338dc258fb95db69c26268801e3b1d3ba246660ac`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00605267 ([`ctg-observation-nct00605267-2012-09-06-3761a85d7766`](#source-ctg-observation-nct00605267-2012-09-06-3761a85d7766))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00605267 at 2026-11-15T21:50:32.222Z. Its registry update date was 2012-09-06, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct00605267-2012-09-06-3761a85d7766`](#source-ctg-observation-nct00605267-2012-09-06-3761a85d7766))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00605267 at 2026-11-15T21:50:32.222Z. Its registry update date was 2012-09-06, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct00605267-2012-09-06-3761a85d7766`](#source-ctg-observation-nct00605267-2012-09-06-3761a85d7766))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00605267-2012-09-06-3761a85d7766`](#source-ctg-observation-nct00605267-2012-09-06-3761a85d7766))

### Sources

<a id="source-ctg-observation-nct00605267-2012-09-06-3761a85d7766"></a>
- **ClinicalTrials.gov record NCT00605267 · retained source version 2012-09-06:3761a85d77664f2df5115c14266aa69ed860bf4953715ca3809738fd394aaa50** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00605267) (`ctg-observation-nct00605267-2012-09-06-3761a85d7766`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00605267." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct00605267-goserelin-v1 SHA-256: f713ffbdf1a1dc3d9bbc32b338dc258fb95db69c26268801e3b1d3ba246660ac.

---

<a id="clinicaltrials-gov-nct01073865-goserelin-v1"></a>

## ClinicalTrials.gov record NCT01073865

> PeptideScanner retained ClinicalTrials.gov record NCT01073865 at 2026-11-15T21:50:32.222Z. Its registry update date was 2018-12-12, and PeptideScanner's reviewed identity mapping was goserelin.

- Evidence object: `story:clinicaltrials-gov-nct01073865-goserelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-12-12
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01073865-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct01073865-goserelin-v1
- Content SHA-256: `038087a9923b7ca59378b37c97ed9ad0d46b218f0644a816fb018c46ba93cdf6`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01073865 ([`ctg-observation-nct01073865-2018-12-12-ce708981b54d`](#source-ctg-observation-nct01073865-2018-12-12-ce708981b54d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01073865 at 2026-11-15T21:50:32.222Z. Its registry update date was 2018-12-12, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct01073865-2018-12-12-ce708981b54d`](#source-ctg-observation-nct01073865-2018-12-12-ce708981b54d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01073865 at 2026-11-15T21:50:32.222Z. Its registry update date was 2018-12-12, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct01073865-2018-12-12-ce708981b54d`](#source-ctg-observation-nct01073865-2018-12-12-ce708981b54d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01073865-2018-12-12-ce708981b54d`](#source-ctg-observation-nct01073865-2018-12-12-ce708981b54d))

### Sources

<a id="source-ctg-observation-nct01073865-2018-12-12-ce708981b54d"></a>
- **ClinicalTrials.gov record NCT01073865 · retained source version 2018-12-12:ce708981b54d94409d0a2f50916167ace9a366059eb53234331ad4070336f063** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01073865) (`ctg-observation-nct01073865-2018-12-12-ce708981b54d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01073865." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct01073865-goserelin-v1 SHA-256: 038087a9923b7ca59378b37c97ed9ad0d46b218f0644a816fb018c46ba93cdf6.

---

<a id="clinicaltrials-gov-nct01250717-goserelin-v1"></a>

## ClinicalTrials.gov record NCT01250717

> PeptideScanner retained ClinicalTrials.gov record NCT01250717 at 2026-11-15T21:50:32.222Z. Its registry update date was 2014-02-04, and PeptideScanner's reviewed identity mapping was goserelin.

- Evidence object: `story:clinicaltrials-gov-nct01250717-goserelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2014-02-04
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01250717-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct01250717-goserelin-v1
- Content SHA-256: `a1b6334df9c708d6729b63390864f88eede348ca44a7b534a2ddbc0585cf2552`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01250717 ([`ctg-observation-nct01250717-2014-02-04-350c0283662c`](#source-ctg-observation-nct01250717-2014-02-04-350c0283662c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01250717 at 2026-11-15T21:50:32.222Z. Its registry update date was 2014-02-04, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct01250717-2014-02-04-350c0283662c`](#source-ctg-observation-nct01250717-2014-02-04-350c0283662c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01250717 at 2026-11-15T21:50:32.222Z. Its registry update date was 2014-02-04, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct01250717-2014-02-04-350c0283662c`](#source-ctg-observation-nct01250717-2014-02-04-350c0283662c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01250717-2014-02-04-350c0283662c`](#source-ctg-observation-nct01250717-2014-02-04-350c0283662c))

### Sources

<a id="source-ctg-observation-nct01250717-2014-02-04-350c0283662c"></a>
- **ClinicalTrials.gov record NCT01250717 · retained source version 2014-02-04:350c0283662c6148de642eab8659e25652696b79d50ae6d33a243ac6f46971a2** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01250717) (`ctg-observation-nct01250717-2014-02-04-350c0283662c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01250717." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct01250717-goserelin-v1 SHA-256: a1b6334df9c708d6729b63390864f88eede348ca44a7b534a2ddbc0585cf2552.

---

<a id="clinicaltrials-gov-nct01496131-goserelin-v1"></a>

## ClinicalTrials.gov record NCT01496131

> PeptideScanner retained ClinicalTrials.gov record NCT01496131 at 2026-11-15T21:50:32.222Z. Its registry update date was 2018-03-09, and PeptideScanner's reviewed identity mapping was goserelin.

- Evidence object: `story:clinicaltrials-gov-nct01496131-goserelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-03-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01496131-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct01496131-goserelin-v1
- Content SHA-256: `7c8cfc681706a38120032d23251aa35eb70c63bc78fe42ccee488d9dd97198c1`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01496131 ([`ctg-observation-nct01496131-2018-03-09-f67f9e9e83cb`](#source-ctg-observation-nct01496131-2018-03-09-f67f9e9e83cb))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01496131 at 2026-11-15T21:50:32.222Z. Its registry update date was 2018-03-09, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct01496131-2018-03-09-f67f9e9e83cb`](#source-ctg-observation-nct01496131-2018-03-09-f67f9e9e83cb))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01496131 at 2026-11-15T21:50:32.222Z. Its registry update date was 2018-03-09, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct01496131-2018-03-09-f67f9e9e83cb`](#source-ctg-observation-nct01496131-2018-03-09-f67f9e9e83cb))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01496131-2018-03-09-f67f9e9e83cb`](#source-ctg-observation-nct01496131-2018-03-09-f67f9e9e83cb))

### Sources

<a id="source-ctg-observation-nct01496131-2018-03-09-f67f9e9e83cb"></a>
- **ClinicalTrials.gov record NCT01496131 · retained source version 2018-03-09:f67f9e9e83cb0de294124fb0c1c32d478aceec2fdd660fbd1a4ccdfa3533e466** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01496131) (`ctg-observation-nct01496131-2018-03-09-f67f9e9e83cb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01496131." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct01496131-goserelin-v1 SHA-256: 7c8cfc681706a38120032d23251aa35eb70c63bc78fe42ccee488d9dd97198c1.

---

<a id="clinicaltrials-gov-nct01682642-goserelin-v1"></a>

## ClinicalTrials.gov record NCT01682642

> PeptideScanner retained ClinicalTrials.gov record NCT01682642 at 2026-11-15T21:50:32.222Z. Its registry update date was 2015-03-20, and PeptideScanner's reviewed identity mapping was goserelin.

- Evidence object: `story:clinicaltrials-gov-nct01682642-goserelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-03-20
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01682642-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct01682642-goserelin-v1
- Content SHA-256: `5b9f72852962e35e9a34bd23bde17ed54c45fff66a2b50e855802386d9413e1a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01682642 ([`ctg-observation-nct01682642-2015-03-20-03a242e38fb6`](#source-ctg-observation-nct01682642-2015-03-20-03a242e38fb6))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01682642 at 2026-11-15T21:50:32.222Z. Its registry update date was 2015-03-20, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct01682642-2015-03-20-03a242e38fb6`](#source-ctg-observation-nct01682642-2015-03-20-03a242e38fb6))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01682642 at 2026-11-15T21:50:32.222Z. Its registry update date was 2015-03-20, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct01682642-2015-03-20-03a242e38fb6`](#source-ctg-observation-nct01682642-2015-03-20-03a242e38fb6))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01682642-2015-03-20-03a242e38fb6`](#source-ctg-observation-nct01682642-2015-03-20-03a242e38fb6))

### Sources

<a id="source-ctg-observation-nct01682642-2015-03-20-03a242e38fb6"></a>
- **ClinicalTrials.gov record NCT01682642 · retained source version 2015-03-20:03a242e38fb6d67d6e24f8b82c8bdbb78c7b24f6b1024ca2070ce253c3404794** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01682642) (`ctg-observation-nct01682642-2015-03-20-03a242e38fb6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01682642." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct01682642-goserelin-v1 SHA-256: 5b9f72852962e35e9a34bd23bde17ed54c45fff66a2b50e855802386d9413e1a.

---

<a id="clinicaltrials-gov-nct01723774-goserelin-v1"></a>

## ClinicalTrials.gov record NCT01723774

> PeptideScanner retained ClinicalTrials.gov record NCT01723774 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-09-25, and PeptideScanner's reviewed identity mapping was goserelin.

- Evidence object: `story:clinicaltrials-gov-nct01723774-goserelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-25
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01723774-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct01723774-goserelin-v1
- Content SHA-256: `05b1ed9106b6b383078454fbf15bfe0bb05029a6ee85f86b590a9d154f9cd076`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01723774 ([`ctg-observation-nct01723774-2026-09-25-e285a9af16fe`](#source-ctg-observation-nct01723774-2026-09-25-e285a9af16fe))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01723774 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-09-25, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct01723774-2026-09-25-e285a9af16fe`](#source-ctg-observation-nct01723774-2026-09-25-e285a9af16fe))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01723774 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-09-25, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct01723774-2026-09-25-e285a9af16fe`](#source-ctg-observation-nct01723774-2026-09-25-e285a9af16fe))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01723774-2026-09-25-e285a9af16fe`](#source-ctg-observation-nct01723774-2026-09-25-e285a9af16fe))

### Sources

<a id="source-ctg-observation-nct01723774-2026-09-25-e285a9af16fe"></a>
- **ClinicalTrials.gov record NCT01723774 · retained source version 2026-09-25:e285a9af16fea7323e239ef9aa8020534f1b4cba1fdb9ffa37a18704d7804a16** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01723774) (`ctg-observation-nct01723774-2026-09-25-e285a9af16fe`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01723774." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct01723774-goserelin-v1 SHA-256: 05b1ed9106b6b383078454fbf15bfe0bb05029a6ee85f86b590a9d154f9cd076.

---

<a id="clinicaltrials-gov-nct02003209-goserelin-v1"></a>

## ClinicalTrials.gov record NCT02003209

> PeptideScanner retained ClinicalTrials.gov record NCT02003209 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-10-06, and PeptideScanner's reviewed identity mapping was goserelin.

- Evidence object: `story:clinicaltrials-gov-nct02003209-goserelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-06
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02003209-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct02003209-goserelin-v1
- Content SHA-256: `af477fcc1bb257159332325244f6241550ab29ad7fad54ed9c0f047a37886433`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02003209 ([`ctg-observation-nct02003209-2026-10-06-27d495d426b3`](#source-ctg-observation-nct02003209-2026-10-06-27d495d426b3))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02003209 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-10-06, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct02003209-2026-10-06-27d495d426b3`](#source-ctg-observation-nct02003209-2026-10-06-27d495d426b3))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02003209 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-10-06, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct02003209-2026-10-06-27d495d426b3`](#source-ctg-observation-nct02003209-2026-10-06-27d495d426b3))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02003209-2026-10-06-27d495d426b3`](#source-ctg-observation-nct02003209-2026-10-06-27d495d426b3))

### Sources

<a id="source-ctg-observation-nct02003209-2026-10-06-27d495d426b3"></a>
- **ClinicalTrials.gov record NCT02003209 · retained source version 2026-10-06:27d495d426b33c7026877cde049408d32ae7d9d17d1f36a06469e93e08f90775** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02003209) (`ctg-observation-nct02003209-2026-10-06-27d495d426b3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02003209." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct02003209-goserelin-v1 SHA-256: af477fcc1bb257159332325244f6241550ab29ad7fad54ed9c0f047a37886433.

---

<a id="clinicaltrials-gov-nct02115282-goserelin-v1"></a>

## ClinicalTrials.gov record NCT02115282

> PeptideScanner retained ClinicalTrials.gov record NCT02115282 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-10-22, and PeptideScanner's reviewed identity mapping was goserelin.

- Evidence object: `story:clinicaltrials-gov-nct02115282-goserelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-22
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02115282-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct02115282-goserelin-v1
- Content SHA-256: `6193c5f8567a323f6442e37d725988d60fe9392e99178fef1263bfba19deb3e7`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02115282 ([`ctg-observation-nct02115282-2026-10-22-2c51d1677454`](#source-ctg-observation-nct02115282-2026-10-22-2c51d1677454))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02115282 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-10-22, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct02115282-2026-10-22-2c51d1677454`](#source-ctg-observation-nct02115282-2026-10-22-2c51d1677454))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02115282 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-10-22, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct02115282-2026-10-22-2c51d1677454`](#source-ctg-observation-nct02115282-2026-10-22-2c51d1677454))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02115282-2026-10-22-2c51d1677454`](#source-ctg-observation-nct02115282-2026-10-22-2c51d1677454))

### Sources

<a id="source-ctg-observation-nct02115282-2026-10-22-2c51d1677454"></a>
- **ClinicalTrials.gov record NCT02115282 · retained source version 2026-10-22:2c51d1677454c6eeac2522fee3b2c390d9fa11204b3bdb62c41a8849ad367765** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02115282) (`ctg-observation-nct02115282-2026-10-22-2c51d1677454`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02115282." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct02115282-goserelin-v1 SHA-256: 6193c5f8567a323f6442e37d725988d60fe9392e99178fef1263bfba19deb3e7.

---

<a id="clinicaltrials-gov-nct02278120-goserelin-v1"></a>

## ClinicalTrials.gov record NCT02278120

> PeptideScanner retained ClinicalTrials.gov record NCT02278120 at 2026-11-15T21:50:32.222Z. Its registry update date was 2024-03-12, and PeptideScanner's reviewed identity mapping was goserelin.

- Evidence object: `story:clinicaltrials-gov-nct02278120-goserelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-03-12
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02278120-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct02278120-goserelin-v1
- Content SHA-256: `5c2995641025665369c6f313e6492b1aba0a7006f2137a4f8675f7b112c55510`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02278120 ([`ctg-observation-nct02278120-2024-03-12-3afae6421a41`](#source-ctg-observation-nct02278120-2024-03-12-3afae6421a41))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02278120 at 2026-11-15T21:50:32.222Z. Its registry update date was 2024-03-12, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct02278120-2024-03-12-3afae6421a41`](#source-ctg-observation-nct02278120-2024-03-12-3afae6421a41))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02278120 at 2026-11-15T21:50:32.222Z. Its registry update date was 2024-03-12, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct02278120-2024-03-12-3afae6421a41`](#source-ctg-observation-nct02278120-2024-03-12-3afae6421a41))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02278120-2024-03-12-3afae6421a41`](#source-ctg-observation-nct02278120-2024-03-12-3afae6421a41))

### Sources

<a id="source-ctg-observation-nct02278120-2024-03-12-3afae6421a41"></a>
- **ClinicalTrials.gov record NCT02278120 · retained source version 2024-03-12:3afae6421a41ee8f75c5b835e6c9561c87f16ee5e11d79633a22d74d00ce747c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02278120) (`ctg-observation-nct02278120-2024-03-12-3afae6421a41`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02278120." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct02278120-goserelin-v1 SHA-256: 5c2995641025665369c6f313e6492b1aba0a7006f2137a4f8675f7b112c55510.

---

<a id="clinicaltrials-gov-nct02430480-goserelin-v1"></a>

## ClinicalTrials.gov record NCT02430480

> PeptideScanner retained ClinicalTrials.gov record NCT02430480 at 2026-11-15T21:50:32.222Z. Its registry update date was 2025-07-16, and PeptideScanner's reviewed identity mapping was goserelin.

- Evidence object: `story:clinicaltrials-gov-nct02430480-goserelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-07-16
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02430480-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct02430480-goserelin-v1
- Content SHA-256: `bf18d793940e866412c6ac6b6ca033b7156994891e1565df13286c001ad3e560`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02430480 ([`ctg-observation-nct02430480-2025-07-16-b163bdd4e2b2`](#source-ctg-observation-nct02430480-2025-07-16-b163bdd4e2b2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02430480 at 2026-11-15T21:50:32.222Z. Its registry update date was 2025-07-16, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct02430480-2025-07-16-b163bdd4e2b2`](#source-ctg-observation-nct02430480-2025-07-16-b163bdd4e2b2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02430480 at 2026-11-15T21:50:32.222Z. Its registry update date was 2025-07-16, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct02430480-2025-07-16-b163bdd4e2b2`](#source-ctg-observation-nct02430480-2025-07-16-b163bdd4e2b2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02430480-2025-07-16-b163bdd4e2b2`](#source-ctg-observation-nct02430480-2025-07-16-b163bdd4e2b2))

### Sources

<a id="source-ctg-observation-nct02430480-2025-07-16-b163bdd4e2b2"></a>
- **ClinicalTrials.gov record NCT02430480 · retained source version 2025-07-16:b163bdd4e2b27f76a480eeb6376c2bc3be30b4cbc4ee0fdf1f7908ba074fbb45** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02430480) (`ctg-observation-nct02430480-2025-07-16-b163bdd4e2b2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02430480." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct02430480-goserelin-v1 SHA-256: bf18d793940e866412c6ac6b6ca033b7156994891e1565df13286c001ad3e560.

---

<a id="clinicaltrials-gov-nct02518191-goserelin-v1"></a>

## ClinicalTrials.gov record NCT02518191

> PeptideScanner retained ClinicalTrials.gov record NCT02518191 at 2026-11-15T21:50:32.222Z. Its registry update date was 2021-06-11, and PeptideScanner's reviewed identity mapping was goserelin.

- Evidence object: `story:clinicaltrials-gov-nct02518191-goserelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-06-11
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02518191-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct02518191-goserelin-v1
- Content SHA-256: `3b21d74613b92c137272f2542e7bd31dc61c76b2c9311f7127690415db5f6cc4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02518191 ([`ctg-observation-nct02518191-2021-06-11-e93f65c8ef98`](#source-ctg-observation-nct02518191-2021-06-11-e93f65c8ef98))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02518191 at 2026-11-15T21:50:32.222Z. Its registry update date was 2021-06-11, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct02518191-2021-06-11-e93f65c8ef98`](#source-ctg-observation-nct02518191-2021-06-11-e93f65c8ef98))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02518191 at 2026-11-15T21:50:32.222Z. Its registry update date was 2021-06-11, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct02518191-2021-06-11-e93f65c8ef98`](#source-ctg-observation-nct02518191-2021-06-11-e93f65c8ef98))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02518191-2021-06-11-e93f65c8ef98`](#source-ctg-observation-nct02518191-2021-06-11-e93f65c8ef98))

### Sources

<a id="source-ctg-observation-nct02518191-2021-06-11-e93f65c8ef98"></a>
- **ClinicalTrials.gov record NCT02518191 · retained source version 2021-06-11:e93f65c8ef9805b34a6180e00b08d803d0ee1857e44271edb9ae11739a6bf7b1** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02518191) (`ctg-observation-nct02518191-2021-06-11-e93f65c8ef98`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02518191." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct02518191-goserelin-v1 SHA-256: 3b21d74613b92c137272f2542e7bd31dc61c76b2c9311f7127690415db5f6cc4.

---

<a id="clinicaltrials-gov-nct02586675-goserelin-v1"></a>

## ClinicalTrials.gov record NCT02586675

> PeptideScanner retained ClinicalTrials.gov record NCT02586675 at 2026-11-15T21:50:32.222Z. Its registry update date was 2022-01-21, and PeptideScanner's reviewed identity mapping was goserelin.

- Evidence object: `story:clinicaltrials-gov-nct02586675-goserelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-01-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02586675-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct02586675-goserelin-v1
- Content SHA-256: `beeadb6496d89335c057dce2227f7c59e94aabf41d8be9ed4d08a0ce99774ed9`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02586675 ([`ctg-observation-nct02586675-2022-01-21-96bf29d42ec5`](#source-ctg-observation-nct02586675-2022-01-21-96bf29d42ec5))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02586675 at 2026-11-15T21:50:32.222Z. Its registry update date was 2022-01-21, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct02586675-2022-01-21-96bf29d42ec5`](#source-ctg-observation-nct02586675-2022-01-21-96bf29d42ec5))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02586675 at 2026-11-15T21:50:32.222Z. Its registry update date was 2022-01-21, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct02586675-2022-01-21-96bf29d42ec5`](#source-ctg-observation-nct02586675-2022-01-21-96bf29d42ec5))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02586675-2022-01-21-96bf29d42ec5`](#source-ctg-observation-nct02586675-2022-01-21-96bf29d42ec5))

### Sources

<a id="source-ctg-observation-nct02586675-2022-01-21-96bf29d42ec5"></a>
- **ClinicalTrials.gov record NCT02586675 · retained source version 2022-01-21:96bf29d42ec53436e424b0a2cac9314bcc9c538b62d9fb7da1ecdc1349398d56** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02586675) (`ctg-observation-nct02586675-2022-01-21-96bf29d42ec5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02586675." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct02586675-goserelin-v1 SHA-256: beeadb6496d89335c057dce2227f7c59e94aabf41d8be9ed4d08a0ce99774ed9.

---

<a id="clinicaltrials-gov-nct03007979-goserelin-v1"></a>

## ClinicalTrials.gov record NCT03007979

> PeptideScanner retained ClinicalTrials.gov record NCT03007979 at 2026-11-15T21:50:32.222Z. Its registry update date was 2024-03-20, and PeptideScanner's reviewed identity mapping was goserelin.

- Evidence object: `story:clinicaltrials-gov-nct03007979-goserelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-03-20
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03007979-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct03007979-goserelin-v1
- Content SHA-256: `d3f48533dc61cadec1ef208870afe101f3f034e7104e1f3821a687ab3702e3af`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03007979 ([`ctg-observation-nct03007979-2024-03-20-7cb77c2876a9`](#source-ctg-observation-nct03007979-2024-03-20-7cb77c2876a9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03007979 at 2026-11-15T21:50:32.222Z. Its registry update date was 2024-03-20, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct03007979-2024-03-20-7cb77c2876a9`](#source-ctg-observation-nct03007979-2024-03-20-7cb77c2876a9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03007979 at 2026-11-15T21:50:32.222Z. Its registry update date was 2024-03-20, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct03007979-2024-03-20-7cb77c2876a9`](#source-ctg-observation-nct03007979-2024-03-20-7cb77c2876a9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03007979-2024-03-20-7cb77c2876a9`](#source-ctg-observation-nct03007979-2024-03-20-7cb77c2876a9))

### Sources

<a id="source-ctg-observation-nct03007979-2024-03-20-7cb77c2876a9"></a>
- **ClinicalTrials.gov record NCT03007979 · retained source version 2024-03-20:7cb77c2876a96f1362d982b61b78c3eed0b4f92c2a870e582cf508e271f3a8da** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03007979) (`ctg-observation-nct03007979-2024-03-20-7cb77c2876a9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03007979." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct03007979-goserelin-v1 SHA-256: d3f48533dc61cadec1ef208870afe101f3f034e7104e1f3821a687ab3702e3af.

---

<a id="clinicaltrials-gov-nct03096847-goserelin-v1"></a>

## ClinicalTrials.gov record NCT03096847

> PeptideScanner retained ClinicalTrials.gov record NCT03096847 at 2026-11-15T21:50:32.222Z. Its registry update date was 2021-10-11, and PeptideScanner's reviewed identity mapping was goserelin.

- Evidence object: `story:clinicaltrials-gov-nct03096847-goserelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-10-11
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03096847-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct03096847-goserelin-v1
- Content SHA-256: `1acfe8fc6f15189cef02a4a81913cc9203a2a8e9bcad74b04f4581c80d25ca2d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03096847 ([`ctg-observation-nct03096847-2021-10-11-200e8b1cf498`](#source-ctg-observation-nct03096847-2021-10-11-200e8b1cf498))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03096847 at 2026-11-15T21:50:32.222Z. Its registry update date was 2021-10-11, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct03096847-2021-10-11-200e8b1cf498`](#source-ctg-observation-nct03096847-2021-10-11-200e8b1cf498))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03096847 at 2026-11-15T21:50:32.222Z. Its registry update date was 2021-10-11, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct03096847-2021-10-11-200e8b1cf498`](#source-ctg-observation-nct03096847-2021-10-11-200e8b1cf498))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03096847-2021-10-11-200e8b1cf498`](#source-ctg-observation-nct03096847-2021-10-11-200e8b1cf498))

### Sources

<a id="source-ctg-observation-nct03096847-2021-10-11-200e8b1cf498"></a>
- **ClinicalTrials.gov record NCT03096847 · retained source version 2021-10-11:200e8b1cf498b6fb2355531882ffa00227e9deaa307e0520368a1bb1381a71e1** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03096847) (`ctg-observation-nct03096847-2021-10-11-200e8b1cf498`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03096847." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct03096847-goserelin-v1 SHA-256: 1acfe8fc6f15189cef02a4a81913cc9203a2a8e9bcad74b04f4581c80d25ca2d.

---

<a id="clinicaltrials-gov-nct03671330-goserelin-v1"></a>

## ClinicalTrials.gov record NCT03671330

> PeptideScanner retained ClinicalTrials.gov record NCT03671330 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-07-08, and PeptideScanner's reviewed identity mapping was goserelin.

- Evidence object: `story:clinicaltrials-gov-nct03671330-goserelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-08
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03671330-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct03671330-goserelin-v1
- Content SHA-256: `f8a38594ff116eca5a6fc60451752e7109d9b5d9d7a34069c52fd8b2ba94cb32`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03671330 ([`ctg-observation-nct03671330-2026-07-08-1594cf8e3449`](#source-ctg-observation-nct03671330-2026-07-08-1594cf8e3449))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03671330 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-07-08, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct03671330-2026-07-08-1594cf8e3449`](#source-ctg-observation-nct03671330-2026-07-08-1594cf8e3449))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03671330 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-07-08, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct03671330-2026-07-08-1594cf8e3449`](#source-ctg-observation-nct03671330-2026-07-08-1594cf8e3449))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03671330-2026-07-08-1594cf8e3449`](#source-ctg-observation-nct03671330-2026-07-08-1594cf8e3449))

### Sources

<a id="source-ctg-observation-nct03671330-2026-07-08-1594cf8e3449"></a>
- **ClinicalTrials.gov record NCT03671330 · retained source version 2026-07-08:1594cf8e3449165b0817217eed41ce9d3a6805ff1aac8443a42fcbd169baf22e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03671330) (`ctg-observation-nct03671330-2026-07-08-1594cf8e3449`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03671330." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct03671330-goserelin-v1 SHA-256: f8a38594ff116eca5a6fc60451752e7109d9b5d9d7a34069c52fd8b2ba94cb32.

---

<a id="clinicaltrials-gov-nct03822468-goserelin-v1"></a>

## ClinicalTrials.gov record NCT03822468

> PeptideScanner retained ClinicalTrials.gov record NCT03822468 at 2026-11-15T21:50:32.222Z. Its registry update date was 2025-10-16, and PeptideScanner's reviewed identity mapping was goserelin.

- Evidence object: `story:clinicaltrials-gov-nct03822468-goserelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-10-16
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03822468-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct03822468-goserelin-v1
- Content SHA-256: `d2fd21aee2e16fde0d7431335dd5460eb0dd7cbc81ffa3c83e16e4766fbfce6d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03822468 ([`ctg-observation-nct03822468-2025-10-16-e32e2ff9d0da`](#source-ctg-observation-nct03822468-2025-10-16-e32e2ff9d0da))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03822468 at 2026-11-15T21:50:32.222Z. Its registry update date was 2025-10-16, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct03822468-2025-10-16-e32e2ff9d0da`](#source-ctg-observation-nct03822468-2025-10-16-e32e2ff9d0da))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03822468 at 2026-11-15T21:50:32.222Z. Its registry update date was 2025-10-16, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct03822468-2025-10-16-e32e2ff9d0da`](#source-ctg-observation-nct03822468-2025-10-16-e32e2ff9d0da))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03822468-2025-10-16-e32e2ff9d0da`](#source-ctg-observation-nct03822468-2025-10-16-e32e2ff9d0da))

### Sources

<a id="source-ctg-observation-nct03822468-2025-10-16-e32e2ff9d0da"></a>
- **ClinicalTrials.gov record NCT03822468 · retained source version 2025-10-16:e32e2ff9d0dad7744d78a5c41de936ddc141b7f51de3e2c9d0956653b29f47e3** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03822468) (`ctg-observation-nct03822468-2025-10-16-e32e2ff9d0da`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03822468." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct03822468-goserelin-v1 SHA-256: d2fd21aee2e16fde0d7431335dd5460eb0dd7cbc81ffa3c83e16e4766fbfce6d.

---

<a id="clinicaltrials-gov-nct03839823-goserelin-v1"></a>

## ClinicalTrials.gov record NCT03839823

> PeptideScanner retained ClinicalTrials.gov record NCT03839823 at 2026-11-15T21:50:32.222Z. Its registry update date was 2024-10-09, and PeptideScanner's reviewed identity mapping was goserelin.

- Evidence object: `story:clinicaltrials-gov-nct03839823-goserelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-10-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03839823-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct03839823-goserelin-v1
- Content SHA-256: `49bd38aed64ff83abed6530af194a749c87549ba92ef0380b27349f2f8448d4a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03839823 ([`ctg-observation-nct03839823-2024-10-09-d15c82136bb1`](#source-ctg-observation-nct03839823-2024-10-09-d15c82136bb1))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03839823 at 2026-11-15T21:50:32.222Z. Its registry update date was 2024-10-09, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct03839823-2024-10-09-d15c82136bb1`](#source-ctg-observation-nct03839823-2024-10-09-d15c82136bb1))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03839823 at 2026-11-15T21:50:32.222Z. Its registry update date was 2024-10-09, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct03839823-2024-10-09-d15c82136bb1`](#source-ctg-observation-nct03839823-2024-10-09-d15c82136bb1))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03839823-2024-10-09-d15c82136bb1`](#source-ctg-observation-nct03839823-2024-10-09-d15c82136bb1))

### Sources

<a id="source-ctg-observation-nct03839823-2024-10-09-d15c82136bb1"></a>
- **ClinicalTrials.gov record NCT03839823 · retained source version 2024-10-09:d15c82136bb190fdf5d96232d9980ffe9426a314ffe0c092bdf4f6a70ad4d517** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03839823) (`ctg-observation-nct03839823-2024-10-09-d15c82136bb1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03839823." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct03839823-goserelin-v1 SHA-256: 49bd38aed64ff83abed6530af194a749c87549ba92ef0380b27349f2f8448d4a.

---

<a id="clinicaltrials-gov-nct05161195-goserelin-v1"></a>

## ClinicalTrials.gov record NCT05161195

> PeptideScanner retained ClinicalTrials.gov record NCT05161195 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-10-19, and PeptideScanner's reviewed identity mapping was goserelin.

- Evidence object: `story:clinicaltrials-gov-nct05161195-goserelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-19
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05161195-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct05161195-goserelin-v1
- Content SHA-256: `6874ba617aa32637a5354bbc844b7474f5f9176ddfe1f0c88fe36fadf6cf686a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05161195 ([`ctg-observation-nct05161195-2026-10-19-022fe9d4cea9`](#source-ctg-observation-nct05161195-2026-10-19-022fe9d4cea9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05161195 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-10-19, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct05161195-2026-10-19-022fe9d4cea9`](#source-ctg-observation-nct05161195-2026-10-19-022fe9d4cea9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05161195 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-10-19, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct05161195-2026-10-19-022fe9d4cea9`](#source-ctg-observation-nct05161195-2026-10-19-022fe9d4cea9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05161195-2026-10-19-022fe9d4cea9`](#source-ctg-observation-nct05161195-2026-10-19-022fe9d4cea9))

### Sources

<a id="source-ctg-observation-nct05161195-2026-10-19-022fe9d4cea9"></a>
- **ClinicalTrials.gov record NCT05161195 · retained source version 2026-10-19:022fe9d4cea9c26754c68969832b935f82a1b959b0c73326ba009726e9da610d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05161195) (`ctg-observation-nct05161195-2026-10-19-022fe9d4cea9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05161195." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct05161195-goserelin-v1 SHA-256: 6874ba617aa32637a5354bbc844b7474f5f9176ddfe1f0c88fe36fadf6cf686a.

---

<a id="clinicaltrials-gov-nct07310420-goserelin-v1"></a>

## ClinicalTrials.gov record NCT07310420

> PeptideScanner retained ClinicalTrials.gov record NCT07310420 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was goserelin.

- Evidence object: `story:clinicaltrials-gov-nct07310420-goserelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-12
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07310420-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct07310420-goserelin-v1
- Content SHA-256: `f308072cb3fa26cc3167fc318de62a40e01f29e15e3e54d409a63f1ff408d5dc`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07310420 ([`ctg-observation-nct07310420-2026-11-12-6b4989ac6fe4`](#source-ctg-observation-nct07310420-2026-11-12-6b4989ac6fe4))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07310420 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct07310420-2026-11-12-6b4989ac6fe4`](#source-ctg-observation-nct07310420-2026-11-12-6b4989ac6fe4))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07310420 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was goserelin. ([`ctg-observation-nct07310420-2026-11-12-6b4989ac6fe4`](#source-ctg-observation-nct07310420-2026-11-12-6b4989ac6fe4))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07310420-2026-11-12-6b4989ac6fe4`](#source-ctg-observation-nct07310420-2026-11-12-6b4989ac6fe4))

### Sources

<a id="source-ctg-observation-nct07310420-2026-11-12-6b4989ac6fe4"></a>
- **ClinicalTrials.gov record NCT07310420 · retained source version 2026-11-12:6b4989ac6fe4da6ded5fde99ec270c627d7e3a5d24d917cacd45d4c8cf5e1e1c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07310420) (`ctg-observation-nct07310420-2026-11-12-6b4989ac6fe4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07310420." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#clinicaltrials-gov-nct07310420-goserelin-v1 SHA-256: f308072cb3fa26cc3167fc318de62a40e01f29e15e3e54d409a63f1ff408d5dc.

---

<a id="fda-drugs-nda019726-v1"></a>

## Drugs@FDA application NDA019726

> The official Drugs@FDA dataset lists original submission 1 for NDA 019726 with status AP dated 1989-12-29, and names goserelin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda019726:v1`
- Evidence domain: Regulatory
- Date in source: 1989-12-29
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda019726/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#fda-drugs-nda019726-v1
- Content SHA-256: `938cb4780ccdccd901de2a108b9dd22d55458da94eee515fb4618af9a3e1dd4a`

### Claims and source pins

#### Headline

Drugs@FDA application NDA019726 ([`fda-drugs-nda019726-1989-12-29-35d6c61d8a86`](#source-fda-drugs-nda019726-1989-12-29-35d6c61d8a86))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 019726 with status AP dated 1989-12-29, and names goserelin acetate among the application record's active ingredients. ([`fda-drugs-nda019726-1989-12-29-35d6c61d8a86`](#source-fda-drugs-nda019726-1989-12-29-35d6c61d8a86))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 019726 with status AP dated 1989-12-29, and names goserelin acetate among the application record's active ingredients. ([`fda-drugs-nda019726-1989-12-29-35d6c61d8a86`](#source-fda-drugs-nda019726-1989-12-29-35d6c61d8a86))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda019726-1989-12-29-35d6c61d8a86`](#source-fda-drugs-nda019726-1989-12-29-35d6c61d8a86))

### Sources

<a id="source-fda-drugs-nda019726-1989-12-29-35d6c61d8a86"></a>
- **Drugs@FDA application NDA019726 · original submission status AP · 1989-12-29 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA019726%22&limit=1) (`fda-drugs-nda019726-1989-12-29-35d6c61d8a86`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA019726." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#fda-drugs-nda019726-v1 SHA-256: 938cb4780ccdccd901de2a108b9dd22d55458da94eee515fb4618af9a3e1dd4a.

---

<a id="fda-drugs-nda020578-v1"></a>

## Drugs@FDA application NDA020578

> The official Drugs@FDA dataset lists original submission 1 for NDA 020578 with status AP dated 1996-01-11, and names goserelin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda020578:v1`
- Evidence domain: Regulatory
- Date in source: 1996-01-11
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda020578/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#fda-drugs-nda020578-v1
- Content SHA-256: `58925c43348e85e8ddce5db2a69c8614eafdb2578decec5ef4ba76779d141e97`

### Claims and source pins

#### Headline

Drugs@FDA application NDA020578 ([`fda-drugs-nda020578-1996-01-11-580ccc5d3c2e`](#source-fda-drugs-nda020578-1996-01-11-580ccc5d3c2e))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 020578 with status AP dated 1996-01-11, and names goserelin acetate among the application record's active ingredients. ([`fda-drugs-nda020578-1996-01-11-580ccc5d3c2e`](#source-fda-drugs-nda020578-1996-01-11-580ccc5d3c2e))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 020578 with status AP dated 1996-01-11, and names goserelin acetate among the application record's active ingredients. ([`fda-drugs-nda020578-1996-01-11-580ccc5d3c2e`](#source-fda-drugs-nda020578-1996-01-11-580ccc5d3c2e))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda020578-1996-01-11-580ccc5d3c2e`](#source-fda-drugs-nda020578-1996-01-11-580ccc5d3c2e))

### Sources

<a id="source-fda-drugs-nda020578-1996-01-11-580ccc5d3c2e"></a>
- **Drugs@FDA application NDA020578 · original submission status AP · 1996-01-11 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA020578%22&limit=1) (`fda-drugs-nda020578-1996-01-11-580ccc5d3c2e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA020578." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#fda-drugs-nda020578-v1 SHA-256: 58925c43348e85e8ddce5db2a69c8614eafdb2578decec5ef4ba76779d141e97.

---

<a id="federal-register-97-10911-v1"></a>

## Federal Register notice 97-10911

> The Federal Register published notice 97-10911, attributed to FDA and its parent HHS department, on 1997-04-28. Its official title is “Environmental Assessments and Findings of No Significant Impact,” and PeptideScanner's exact reviewed identity mapping connects the document to Goserelin.

- Evidence object: `story:federal-register-97-10911:v1`
- Evidence domain: Regulatory
- Date in source: 1997-04-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-97-10911/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#federal-register-97-10911-v1
- Content SHA-256: `0b307b7906ac6171b1369b1147378121c72f4141865491afda14ba206dbb9a4c`

### Claims and source pins

#### Headline

Federal Register notice 97-10911 ([`federal-register-97-10911-4b6241c29652`](#source-federal-register-97-10911-4b6241c29652))

#### Summary

The Federal Register published notice 97-10911, attributed to FDA and its parent HHS department, on 1997-04-28. Its official title is “Environmental Assessments and Findings of No Significant Impact,” and PeptideScanner's exact reviewed identity mapping connects the document to Goserelin. ([`federal-register-97-10911-4b6241c29652`](#source-federal-register-97-10911-4b6241c29652))

#### Paragraph 1

The Federal Register published notice 97-10911, attributed to FDA and its parent HHS department, on 1997-04-28. Its official title is “Environmental Assessments and Findings of No Significant Impact,” and PeptideScanner's exact reviewed identity mapping connects the document to Goserelin. ([`federal-register-97-10911-4b6241c29652`](#source-federal-register-97-10911-4b6241c29652))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-97-10911-4b6241c29652`](#source-federal-register-97-10911-4b6241c29652))

### Sources

<a id="source-federal-register-97-10911-4b6241c29652"></a>
- **Federal Register notice 97-10911 · published 1997-04-28 · Environmental Assessments and Findings of No Significant Impact** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-1997-04-28/pdf/97-10911.pdf) (`federal-register-97-10911-4b6241c29652`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 97-10911." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#federal-register-97-10911-v1 SHA-256: 0b307b7906ac6171b1369b1147378121c72f4141865491afda14ba206dbb9a4c.

---

<a id="pubmed-pmid-12183859-goserelin-v1"></a>

## Treating relapsed epithelial ovarian cancer with luteinizing hormone-releasing agonist (goserelin) after failure of chemotherapy.

> PubMed lists PMID 12183859 in The Israel Medical Association journal : IMAJ as Clinical Trial, Journal Article, with publication-date metadata of 2002-08 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-12183859-goserelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-12183859-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-12183859-goserelin-v1
- Content SHA-256: `e1ca300dbecf33fd6f4fb499ea7b9720b2c027883dc18b0a0b8b324efadf4548`

### Claims and source pins

#### Headline

Treating relapsed epithelial ovarian cancer with luteinizing hormone-releasing agonist (goserelin) after failure of chemotherapy. ([`pubmed-observation-pmid-12183859-2013-11-21-5281f952c7cc`](#source-pubmed-observation-pmid-12183859-2013-11-21-5281f952c7cc))

#### Summary

PubMed lists PMID 12183859 in The Israel Medical Association journal : IMAJ as Clinical Trial, Journal Article, with publication-date metadata of 2002-08 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-12183859-2013-11-21-5281f952c7cc`](#source-pubmed-observation-pmid-12183859-2013-11-21-5281f952c7cc))

#### Paragraph 1

PubMed lists PMID 12183859 in The Israel Medical Association journal : IMAJ as Clinical Trial, Journal Article, with publication-date metadata of 2002-08 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-12183859-2013-11-21-5281f952c7cc`](#source-pubmed-observation-pmid-12183859-2013-11-21-5281f952c7cc))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-12183859-2013-11-21-5281f952c7cc`](#source-pubmed-observation-pmid-12183859-2013-11-21-5281f952c7cc))

### Sources

<a id="source-pubmed-observation-pmid-12183859-2013-11-21-5281f952c7cc"></a>
- **Treating relapsed epithelial ovarian cancer with luteinizing hormone-releasing agonist (goserelin) after failure of chemotherapy. · retained source version 1:2013-11-21:current:5281f952c7ccbf3bf20274246fc6be593e624646269f04516c5914985a8a01b3** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/12183859/) (`pubmed-observation-pmid-12183859-2013-11-21-5281f952c7cc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Treating relapsed epithelial ovarian cancer with luteinizing hormone-releasing agonist (goserelin) after failure of chemotherapy." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-12183859-goserelin-v1 SHA-256: e1ca300dbecf33fd6f4fb499ea7b9720b2c027883dc18b0a0b8b324efadf4548.

---

<a id="pubmed-pmid-12217302-goserelin-v1"></a>

## Adjuvant endocrine treatment (goserelin vs tamoxifen) in pre-menopausal patients with operable node positive stage II breast cancer. A prospective randomized national multicenter study.

> PubMed lists PMID 12217302 in European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology as Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, and 1 more PubMed publication type, with publication-date metadata of 2002-08 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-12217302-goserelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-11-06
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-12217302-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-12217302-goserelin-v1
- Content SHA-256: `5d0101c2147e85873dcd5ab6e4ddd871fdc539dfa0c57b2f5e79658a49c3bc2d`

### Claims and source pins

#### Headline

Adjuvant endocrine treatment (goserelin vs tamoxifen) in pre-menopausal patients with operable node positive stage II breast cancer. A prospective randomized national multicenter study. ([`pubmed-observation-pmid-12217302-2019-11-06-b910327fe733`](#source-pubmed-observation-pmid-12217302-2019-11-06-b910327fe733))

#### Summary

PubMed lists PMID 12217302 in European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology as Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, and 1 more PubMed publication type, with publication-date metadata of 2002-08 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-12217302-2019-11-06-b910327fe733`](#source-pubmed-observation-pmid-12217302-2019-11-06-b910327fe733))

#### Paragraph 1

PubMed lists PMID 12217302 in European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology as Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, and 1 more PubMed publication type, with publication-date metadata of 2002-08 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-12217302-2019-11-06-b910327fe733`](#source-pubmed-observation-pmid-12217302-2019-11-06-b910327fe733))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-12217302-2019-11-06-b910327fe733`](#source-pubmed-observation-pmid-12217302-2019-11-06-b910327fe733))

### Sources

<a id="source-pubmed-observation-pmid-12217302-2019-11-06-b910327fe733"></a>
- **Adjuvant endocrine treatment (goserelin vs tamoxifen) in pre-menopausal patients with operable node positive stage II breast cancer. A prospective randomized national multicenter study. · retained source version 1:2019-11-06:current:b910327fe733ef338b04171b16f1bfeabf377e93428a550828cf75edbe385a11** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/12217302/) (`pubmed-observation-pmid-12217302-2019-11-06-b910327fe733`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Adjuvant endocrine treatment (goserelin vs tamoxifen) in pre-menopausal patients with operable node positive stage II breast cancer. A prospective randomized national multicenter study." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-12217302-goserelin-v1 SHA-256: 5d0101c2147e85873dcd5ab6e4ddd871fdc539dfa0c57b2f5e79658a49c3bc2d.

---

<a id="pubmed-pmid-12477997-goserelin-v1"></a>

## Goserelin acetate as treatment for recurrent endometrial carcinoma: a Gynecologic Oncology Group study.

> PubMed lists PMID 12477997 in American journal of clinical oncology as Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S., with publication-date metadata of 2002-12 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-12477997-goserelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-09-06
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-12477997-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-12477997-goserelin-v1
- Content SHA-256: `5c7886973fcc6a416ea3117cc669ff0400a7444ca8e5d1fce0e1ca8f46b95647`

### Claims and source pins

#### Headline

Goserelin acetate as treatment for recurrent endometrial carcinoma: a Gynecologic Oncology Group study. ([`pubmed-observation-pmid-12477997-2019-09-06-50a67ff45d55`](#source-pubmed-observation-pmid-12477997-2019-09-06-50a67ff45d55))

#### Summary

PubMed lists PMID 12477997 in American journal of clinical oncology as Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S., with publication-date metadata of 2002-12 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-12477997-2019-09-06-50a67ff45d55`](#source-pubmed-observation-pmid-12477997-2019-09-06-50a67ff45d55))

#### Paragraph 1

PubMed lists PMID 12477997 in American journal of clinical oncology as Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S., with publication-date metadata of 2002-12 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-12477997-2019-09-06-50a67ff45d55`](#source-pubmed-observation-pmid-12477997-2019-09-06-50a67ff45d55))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-12477997-2019-09-06-50a67ff45d55`](#source-pubmed-observation-pmid-12477997-2019-09-06-50a67ff45d55))

### Sources

<a id="source-pubmed-observation-pmid-12477997-2019-09-06-50a67ff45d55"></a>
- **Goserelin acetate as treatment for recurrent endometrial carcinoma: a Gynecologic Oncology Group study. · retained source version 1:2019-09-06:current:50a67ff45d55e0e2ded0153173a54e9eddb25a87f04e99c06f78947d44761a8f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/12477997/) (`pubmed-observation-pmid-12477997-2019-09-06-50a67ff45d55`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Goserelin acetate as treatment for recurrent endometrial carcinoma: a Gynecologic Oncology Group study." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-12477997-goserelin-v1 SHA-256: 5c7886973fcc6a416ea3117cc669ff0400a7444ca8e5d1fce0e1ca8f46b95647.

---

<a id="pubmed-pmid-12488405-goserelin-v1"></a>

## Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patien…

> PubMed lists PMID 12488405 in Journal of clinical oncology : official journal of the American Society of Clinical Oncology as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2002-12-15 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-12488405-goserelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-02
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-12488405-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-12488405-goserelin-v1
- Content SHA-256: `c06077872c3558616ccc1ac45f0a767a32ffd63bc3d2694cc36e63aaf96bcd94`

### Claims and source pins

#### Headline

Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patien… ([`pubmed-observation-pmid-12488405-2016-11-02-c21fff07bdd5`](#source-pubmed-observation-pmid-12488405-2016-11-02-c21fff07bdd5))

#### Summary

PubMed lists PMID 12488405 in Journal of clinical oncology : official journal of the American Society of Clinical Oncology as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2002-12-15 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-12488405-2016-11-02-c21fff07bdd5`](#source-pubmed-observation-pmid-12488405-2016-11-02-c21fff07bdd5))

#### Paragraph 1

PubMed lists PMID 12488405 in Journal of clinical oncology : official journal of the American Society of Clinical Oncology as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2002-12-15 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-12488405-2016-11-02-c21fff07bdd5`](#source-pubmed-observation-pmid-12488405-2016-11-02-c21fff07bdd5))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-12488405-2016-11-02-c21fff07bdd5`](#source-pubmed-observation-pmid-12488405-2016-11-02-c21fff07bdd5))

### Sources

<a id="source-pubmed-observation-pmid-12488405-2016-11-02-c21fff07bdd5"></a>
- **Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5. · retained source version 1:2016-11-02:current:c21fff07bdd555c329a2b005bb17ac016288dd9e5aff926243132d8821bf228c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/12488405/) (`pubmed-observation-pmid-12488405-2016-11-02-c21fff07bdd5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patien…." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-12488405-goserelin-v1 SHA-256: c06077872c3558616ccc1ac45f0a767a32ffd63bc3d2694cc36e63aaf96bcd94.

---

<a id="pubmed-pmid-14530912-goserelin-v1"></a>

## Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF).

> PubMed lists PMID 14530912 in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA as Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2003-10-03 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-14530912-goserelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-11-13
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-14530912-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-14530912-goserelin-v1
- Content SHA-256: `41d765d411a0a20e4a9f9cf18c5ae39ba61240d752b1d99bc5b3ebdedc8376f0`

### Claims and source pins

#### Headline

Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). ([`pubmed-observation-pmid-14530912-2018-11-13-6d420b688069`](#source-pubmed-observation-pmid-14530912-2018-11-13-6d420b688069))

#### Summary

PubMed lists PMID 14530912 in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA as Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2003-10-03 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-14530912-2018-11-13-6d420b688069`](#source-pubmed-observation-pmid-14530912-2018-11-13-6d420b688069))

#### Paragraph 1

PubMed lists PMID 14530912 in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA as Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2003-10-03 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-14530912-2018-11-13-6d420b688069`](#source-pubmed-observation-pmid-14530912-2018-11-13-6d420b688069))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-14530912-2018-11-13-6d420b688069`](#source-pubmed-observation-pmid-14530912-2018-11-13-6d420b688069))

### Sources

<a id="source-pubmed-observation-pmid-14530912-2018-11-13-6d420b688069"></a>
- **Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). · retained source version 1:2018-11-13:current:6d420b688069797fbcd7c154d3b05c7207b71442cc2cb3e15549b96432c4ea7c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/14530912/) (`pubmed-observation-pmid-14530912-2018-11-13-6d420b688069`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-14530912-goserelin-v1 SHA-256: 41d765d411a0a20e4a9f9cf18c5ae39ba61240d752b1d99bc5b3ebdedc8376f0.

---

<a id="pubmed-pmid-14679153-goserelin-v1"></a>

## Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.

> PubMed lists PMID 14679153 in Journal of the National Cancer Institute as Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, and 1 more PubMed publication type, with publication-date metadata of 2003-12-17 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-14679153-goserelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-03-31
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-14679153-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-14679153-goserelin-v1
- Content SHA-256: `cbecf5a946eb149da997ab1d2fa7343388388097b61ad850a7fe81b059e49770`

### Claims and source pins

#### Headline

Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. ([`pubmed-observation-pmid-14679153-2022-03-31-5fa152248997`](#source-pubmed-observation-pmid-14679153-2022-03-31-5fa152248997))

#### Summary

PubMed lists PMID 14679153 in Journal of the National Cancer Institute as Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, and 1 more PubMed publication type, with publication-date metadata of 2003-12-17 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-14679153-2022-03-31-5fa152248997`](#source-pubmed-observation-pmid-14679153-2022-03-31-5fa152248997))

#### Paragraph 1

PubMed lists PMID 14679153 in Journal of the National Cancer Institute as Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, and 1 more PubMed publication type, with publication-date metadata of 2003-12-17 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-14679153-2022-03-31-5fa152248997`](#source-pubmed-observation-pmid-14679153-2022-03-31-5fa152248997))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-14679153-2022-03-31-5fa152248997`](#source-pubmed-observation-pmid-14679153-2022-03-31-5fa152248997))

### Sources

<a id="source-pubmed-observation-pmid-14679153-2022-03-31-5fa152248997"></a>
- **Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. · retained source version 1:2022-03-31:current:5fa1522489975656d7b41ab76415651d25e0adfc786760db626de58cfa0b2a56** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/14679153/) (`pubmed-observation-pmid-14679153-2022-03-31-5fa152248997`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-14679153-goserelin-v1 SHA-256: cbecf5a946eb149da997ab1d2fa7343388388097b61ad850a7fe81b059e49770.

---

<a id="pubmed-pmid-14760369-goserelin-v1"></a>

## Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.

> PubMed lists PMID 14760369 in British journal of cancer as Clinical Trial, Journal Article, with publication-date metadata of 2004-02-09 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-14760369-goserelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-03-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-14760369-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-14760369-goserelin-v1
- Content SHA-256: `0b7c06a89fead5c6ffe47ead0fd80e0844104e728d4ddbbcc862e7864ebc447b`

### Claims and source pins

#### Headline

Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. ([`pubmed-observation-pmid-14760369-2022-03-09-0ee3748b7eea`](#source-pubmed-observation-pmid-14760369-2022-03-09-0ee3748b7eea))

#### Summary

PubMed lists PMID 14760369 in British journal of cancer as Clinical Trial, Journal Article, with publication-date metadata of 2004-02-09 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-14760369-2022-03-09-0ee3748b7eea`](#source-pubmed-observation-pmid-14760369-2022-03-09-0ee3748b7eea))

#### Paragraph 1

PubMed lists PMID 14760369 in British journal of cancer as Clinical Trial, Journal Article, with publication-date metadata of 2004-02-09 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-14760369-2022-03-09-0ee3748b7eea`](#source-pubmed-observation-pmid-14760369-2022-03-09-0ee3748b7eea))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-14760369-2022-03-09-0ee3748b7eea`](#source-pubmed-observation-pmid-14760369-2022-03-09-0ee3748b7eea))

### Sources

<a id="source-pubmed-observation-pmid-14760369-2022-03-09-0ee3748b7eea"></a>
- **Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. · retained source version 1:2022-03-09:current:0ee3748b7eea8f30e29acd284518ff0013b9cd218e4ac375ce85a53673d91b20** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/14760369/) (`pubmed-observation-pmid-14760369-2022-03-09-0ee3748b7eea`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-14760369-goserelin-v1 SHA-256: 0b7c06a89fead5c6ffe47ead0fd80e0844104e728d4ddbbcc862e7864ebc447b.

---

<a id="pubmed-pmid-15590321-goserelin-v1"></a>

## Goserelin ('Zoladex')--offering patients more choice in early breast cancer.

> PubMed lists PMID 15590321 in European journal of oncology nursing : the official journal of European Oncology Nursing Society as Journal Article, Review, with publication-date metadata of 2004 (year precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15590321-goserelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15590321-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-15590321-goserelin-v1
- Content SHA-256: `935d8f30823affb541b5bb0d04e6938cc4baf50f841a5df7ecd8fada576d534f`

### Claims and source pins

#### Headline

Goserelin ('Zoladex')--offering patients more choice in early breast cancer. ([`pubmed-observation-pmid-15590321-2026-01-28-2e2f1cc96ff7`](#source-pubmed-observation-pmid-15590321-2026-01-28-2e2f1cc96ff7))

#### Summary

PubMed lists PMID 15590321 in European journal of oncology nursing : the official journal of European Oncology Nursing Society as Journal Article, Review, with publication-date metadata of 2004 (year precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15590321-2026-01-28-2e2f1cc96ff7`](#source-pubmed-observation-pmid-15590321-2026-01-28-2e2f1cc96ff7))

#### Paragraph 1

PubMed lists PMID 15590321 in European journal of oncology nursing : the official journal of European Oncology Nursing Society as Journal Article, Review, with publication-date metadata of 2004 (year precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15590321-2026-01-28-2e2f1cc96ff7`](#source-pubmed-observation-pmid-15590321-2026-01-28-2e2f1cc96ff7))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15590321-2026-01-28-2e2f1cc96ff7`](#source-pubmed-observation-pmid-15590321-2026-01-28-2e2f1cc96ff7))

### Sources

<a id="source-pubmed-observation-pmid-15590321-2026-01-28-2e2f1cc96ff7"></a>
- **Goserelin ('Zoladex')--offering patients more choice in early breast cancer. · retained source version 1:2026-01-28:current:2e2f1cc96ff7fd504e005fe30d43bc24658947d4d370f7358bb6d49dd791595a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15590321/) (`pubmed-observation-pmid-15590321-2026-01-28-2e2f1cc96ff7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Goserelin ('Zoladex')--offering patients more choice in early breast cancer." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-15590321-goserelin-v1 SHA-256: 935d8f30823affb541b5bb0d04e6938cc4baf50f841a5df7ecd8fada576d534f.

---

<a id="pubmed-pmid-15592276-goserelin-v1"></a>

## European randomized, multicenter study of goserelin (Zoladex) in the management of mastalgia.

> PubMed lists PMID 15592276 in American journal of obstetrics and gynecology as Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, and 1 more PubMed publication type, with publication-date metadata of 2004-12 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15592276-goserelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15592276-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-15592276-goserelin-v1
- Content SHA-256: `a05cd202966875ec3fc0144e658d15cc54b737c42478aa0763521370df767118`

### Claims and source pins

#### Headline

European randomized, multicenter study of goserelin (Zoladex) in the management of mastalgia. ([`pubmed-observation-pmid-15592276-2013-11-21-cb5e4203fa01`](#source-pubmed-observation-pmid-15592276-2013-11-21-cb5e4203fa01))

#### Summary

PubMed lists PMID 15592276 in American journal of obstetrics and gynecology as Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, and 1 more PubMed publication type, with publication-date metadata of 2004-12 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15592276-2013-11-21-cb5e4203fa01`](#source-pubmed-observation-pmid-15592276-2013-11-21-cb5e4203fa01))

#### Paragraph 1

PubMed lists PMID 15592276 in American journal of obstetrics and gynecology as Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, and 1 more PubMed publication type, with publication-date metadata of 2004-12 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15592276-2013-11-21-cb5e4203fa01`](#source-pubmed-observation-pmid-15592276-2013-11-21-cb5e4203fa01))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15592276-2013-11-21-cb5e4203fa01`](#source-pubmed-observation-pmid-15592276-2013-11-21-cb5e4203fa01))

### Sources

<a id="source-pubmed-observation-pmid-15592276-2013-11-21-cb5e4203fa01"></a>
- **European randomized, multicenter study of goserelin (Zoladex) in the management of mastalgia. · retained source version 1:2013-11-21:current:cb5e4203fa0156c5a42f91276cc1ee475f6e9dffc19f0daeca0cf44bda1ef7fb** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15592276/) (`pubmed-observation-pmid-15592276-2013-11-21-cb5e4203fa01`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "European randomized, multicenter study of goserelin (Zoladex) in the management of mastalgia." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-15592276-goserelin-v1 SHA-256: a05cd202966875ec3fc0144e658d15cc54b737c42478aa0763521370df767118.

---

<a id="pubmed-pmid-15668708-goserelin-v1"></a>

## A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer.

> PubMed lists PMID 15668708 in British journal of cancer as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2005-02-14 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15668708-goserelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-08-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15668708-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-15668708-goserelin-v1
- Content SHA-256: `b475f1ab6405f2792497bee22f507880f5a4474f7d1b0e204295cf4facc719d7`

### Claims and source pins

#### Headline

A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer. ([`pubmed-observation-pmid-15668708-2024-08-21-8b7aac649f7a`](#source-pubmed-observation-pmid-15668708-2024-08-21-8b7aac649f7a))

#### Summary

PubMed lists PMID 15668708 in British journal of cancer as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2005-02-14 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15668708-2024-08-21-8b7aac649f7a`](#source-pubmed-observation-pmid-15668708-2024-08-21-8b7aac649f7a))

#### Paragraph 1

PubMed lists PMID 15668708 in British journal of cancer as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2005-02-14 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15668708-2024-08-21-8b7aac649f7a`](#source-pubmed-observation-pmid-15668708-2024-08-21-8b7aac649f7a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15668708-2024-08-21-8b7aac649f7a`](#source-pubmed-observation-pmid-15668708-2024-08-21-8b7aac649f7a))

### Sources

<a id="source-pubmed-observation-pmid-15668708-2024-08-21-8b7aac649f7a"></a>
- **A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer. · retained source version 1:2024-08-21:current:8b7aac649f7afc0fb3c61fd844497006c668948dabc6f1b11993f094ad2fdcb7** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15668708/) (`pubmed-observation-pmid-15668708-2024-08-21-8b7aac649f7a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-15668708-goserelin-v1 SHA-256: b475f1ab6405f2792497bee22f507880f5a4474f7d1b0e204295cf4facc719d7.

---

<a id="pubmed-pmid-16111461-goserelin-v1"></a>

## Use of goserelin in the treatment of breast cancer.

> PubMed lists PMID 16111461 in Expert review of anticancer therapy as Journal Article, Review, with publication-date metadata of 2005-08 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-16111461-goserelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-16111461-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-16111461-goserelin-v1
- Content SHA-256: `278f308cef3f3883cc131602c8cdcb4b1ec73dfae1fb82ffab8d16cb1f82ece1`

### Claims and source pins

#### Headline

Use of goserelin in the treatment of breast cancer. ([`pubmed-observation-pmid-16111461-2013-11-21-d930d72ce2ce`](#source-pubmed-observation-pmid-16111461-2013-11-21-d930d72ce2ce))

#### Summary

PubMed lists PMID 16111461 in Expert review of anticancer therapy as Journal Article, Review, with publication-date metadata of 2005-08 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16111461-2013-11-21-d930d72ce2ce`](#source-pubmed-observation-pmid-16111461-2013-11-21-d930d72ce2ce))

#### Paragraph 1

PubMed lists PMID 16111461 in Expert review of anticancer therapy as Journal Article, Review, with publication-date metadata of 2005-08 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16111461-2013-11-21-d930d72ce2ce`](#source-pubmed-observation-pmid-16111461-2013-11-21-d930d72ce2ce))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-16111461-2013-11-21-d930d72ce2ce`](#source-pubmed-observation-pmid-16111461-2013-11-21-d930d72ce2ce))

### Sources

<a id="source-pubmed-observation-pmid-16111461-2013-11-21-d930d72ce2ce"></a>
- **Use of goserelin in the treatment of breast cancer. · retained source version 1:2013-11-21:current:d930d72ce2ce0a6e445d0eea8b5f53992bafb197ab988a777b1689164302fb4c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/16111461/) (`pubmed-observation-pmid-16111461-2013-11-21-d930d72ce2ce`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Use of goserelin in the treatment of breast cancer." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-16111461-goserelin-v1 SHA-256: 278f308cef3f3883cc131602c8cdcb4b1ec73dfae1fb82ffab8d16cb1f82ece1.

---

<a id="pubmed-pmid-16222310-goserelin-v1"></a>

## Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer.

> PubMed lists PMID 16222310 in British journal of cancer as Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2005-09-19 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-16222310-goserelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-03-16
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-16222310-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-16222310-goserelin-v1
- Content SHA-256: `fc1aa6071e08985ab2dc8ed445efbc7bd894fa779bf281f5ab59fb3757eabc1d`

### Claims and source pins

#### Headline

Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer. ([`pubmed-observation-pmid-16222310-2022-03-16-2dc1b8a5d512`](#source-pubmed-observation-pmid-16222310-2022-03-16-2dc1b8a5d512))

#### Summary

PubMed lists PMID 16222310 in British journal of cancer as Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2005-09-19 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16222310-2022-03-16-2dc1b8a5d512`](#source-pubmed-observation-pmid-16222310-2022-03-16-2dc1b8a5d512))

#### Paragraph 1

PubMed lists PMID 16222310 in British journal of cancer as Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2005-09-19 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16222310-2022-03-16-2dc1b8a5d512`](#source-pubmed-observation-pmid-16222310-2022-03-16-2dc1b8a5d512))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-16222310-2022-03-16-2dc1b8a5d512`](#source-pubmed-observation-pmid-16222310-2022-03-16-2dc1b8a5d512))

### Sources

<a id="source-pubmed-observation-pmid-16222310-2022-03-16-2dc1b8a5d512"></a>
- **Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer. · retained source version 1:2022-03-16:current:2dc1b8a5d512391ca0ecd7590e053036ebdcca389299db2f42d462a88e4644e9** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/16222310/) (`pubmed-observation-pmid-16222310-2022-03-16-2dc1b8a5d512`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-16222310-goserelin-v1 SHA-256: fc1aa6071e08985ab2dc8ed445efbc7bd894fa779bf281f5ab59fb3757eabc1d.

---

<a id="pubmed-pmid-16352931-goserelin-v1"></a>

## \[Assessment of goserelin treatment in adjuvant therapy for premenopausal patients with breast cancer in Japan-zoladex breast cancer study group trial-B\].

> PubMed lists PMID 16352931 in Gan to kagaku ryoho. Cancer & chemotherapy as English Abstract, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2005-12 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-16352931-goserelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-16352931-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-16352931-goserelin-v1
- Content SHA-256: `e082492bce28f28a3b15307c8ae848b6ea6d6a7ef5d69d7772178d81239248cf`

### Claims and source pins

#### Headline

\[Assessment of goserelin treatment in adjuvant therapy for premenopausal patients with breast cancer in Japan-zoladex breast cancer study group trial-B\]. ([`pubmed-observation-pmid-16352931-2013-11-21-ce4bedf677d2`](#source-pubmed-observation-pmid-16352931-2013-11-21-ce4bedf677d2))

#### Summary

PubMed lists PMID 16352931 in Gan to kagaku ryoho. Cancer & chemotherapy as English Abstract, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2005-12 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16352931-2013-11-21-ce4bedf677d2`](#source-pubmed-observation-pmid-16352931-2013-11-21-ce4bedf677d2))

#### Paragraph 1

PubMed lists PMID 16352931 in Gan to kagaku ryoho. Cancer & chemotherapy as English Abstract, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2005-12 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16352931-2013-11-21-ce4bedf677d2`](#source-pubmed-observation-pmid-16352931-2013-11-21-ce4bedf677d2))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-16352931-2013-11-21-ce4bedf677d2`](#source-pubmed-observation-pmid-16352931-2013-11-21-ce4bedf677d2))

### Sources

<a id="source-pubmed-observation-pmid-16352931-2013-11-21-ce4bedf677d2"></a>
- **\[Assessment of goserelin treatment in adjuvant therapy for premenopausal patients with breast cancer in Japan-zoladex breast cancer study group trial-B\]. · retained source version 1:2013-11-21:current:ce4bedf677d2e3dec0622e382e90416c4152770e373e24683113569398dd910f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/16352931/) (`pubmed-observation-pmid-16352931-2013-11-21-ce4bedf677d2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Assessment of goserelin treatment in adjuvant therapy for premenopausal patients with breast cancer in Japan-zoladex breast cancer study group trial-B\]." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-16352931-goserelin-v1 SHA-256: e082492bce28f28a3b15307c8ae848b6ea6d6a7ef5d69d7772178d81239248cf.

---

<a id="pubmed-pmid-16392882-goserelin-v1"></a>

## Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women.

> PubMed lists PMID 16392882 in Drugs as Journal Article, Review, with publication-date metadata of 2005 (year precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-16392882-goserelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-11-13
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-16392882-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-16392882-goserelin-v1
- Content SHA-256: `d8d2d3a46fe9d6f0da083e9fa53332ac3efdfac29b9129589fcf9653ef57ceb8`

### Claims and source pins

#### Headline

Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women. ([`pubmed-observation-pmid-16392882-2018-11-13-a65ee9c3f174`](#source-pubmed-observation-pmid-16392882-2018-11-13-a65ee9c3f174))

#### Summary

PubMed lists PMID 16392882 in Drugs as Journal Article, Review, with publication-date metadata of 2005 (year precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16392882-2018-11-13-a65ee9c3f174`](#source-pubmed-observation-pmid-16392882-2018-11-13-a65ee9c3f174))

#### Paragraph 1

PubMed lists PMID 16392882 in Drugs as Journal Article, Review, with publication-date metadata of 2005 (year precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16392882-2018-11-13-a65ee9c3f174`](#source-pubmed-observation-pmid-16392882-2018-11-13-a65ee9c3f174))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-16392882-2018-11-13-a65ee9c3f174`](#source-pubmed-observation-pmid-16392882-2018-11-13-a65ee9c3f174))

### Sources

<a id="source-pubmed-observation-pmid-16392882-2018-11-13-a65ee9c3f174"></a>
- **Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women. · retained source version 1:2018-11-13:current:a65ee9c3f1743c6b8e436719f127174b3dbeac6a911bd6f1f52bd6d97c4b947a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/16392882/) (`pubmed-observation-pmid-16392882-2018-11-13-a65ee9c3f174`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-16392882-goserelin-v1 SHA-256: d8d2d3a46fe9d6f0da083e9fa53332ac3efdfac29b9129589fcf9653ef57ceb8.

---

<a id="pubmed-pmid-16637313-goserelin-v1"></a>

## \[Hysteroresection of submucous myomas after treatment with zoladex\].

> PubMed lists PMID 16637313 in Akusherstvo i ginekologiia as Clinical Trial, English Abstract, Journal Article, with publication-date metadata of 2006 (year precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-16637313-goserelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-16637313-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-16637313-goserelin-v1
- Content SHA-256: `d1eff25ca9b771460a5bdc1ef97225f90281ad385dedf7425bae83242ba37024`

### Claims and source pins

#### Headline

\[Hysteroresection of submucous myomas after treatment with zoladex\]. ([`pubmed-observation-pmid-16637313-2013-11-21-4e2e71affae0`](#source-pubmed-observation-pmid-16637313-2013-11-21-4e2e71affae0))

#### Summary

PubMed lists PMID 16637313 in Akusherstvo i ginekologiia as Clinical Trial, English Abstract, Journal Article, with publication-date metadata of 2006 (year precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16637313-2013-11-21-4e2e71affae0`](#source-pubmed-observation-pmid-16637313-2013-11-21-4e2e71affae0))

#### Paragraph 1

PubMed lists PMID 16637313 in Akusherstvo i ginekologiia as Clinical Trial, English Abstract, Journal Article, with publication-date metadata of 2006 (year precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16637313-2013-11-21-4e2e71affae0`](#source-pubmed-observation-pmid-16637313-2013-11-21-4e2e71affae0))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-16637313-2013-11-21-4e2e71affae0`](#source-pubmed-observation-pmid-16637313-2013-11-21-4e2e71affae0))

### Sources

<a id="source-pubmed-observation-pmid-16637313-2013-11-21-4e2e71affae0"></a>
- **\[Hysteroresection of submucous myomas after treatment with zoladex\]. · retained source version 1:2013-11-21:current:4e2e71affae07d38631a47f664e84f14d4323040ea65083361b44a3d1cdb535d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/16637313/) (`pubmed-observation-pmid-16637313-2013-11-21-4e2e71affae0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Hysteroresection of submucous myomas after treatment with zoladex\]." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-16637313-goserelin-v1 SHA-256: d1eff25ca9b771460a5bdc1ef97225f90281ad385dedf7425bae83242ba37024.

---

<a id="pubmed-pmid-16765589-goserelin-v1"></a>

## CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93).

> PubMed lists PMID 16765589 in European journal of cancer (Oxford, England : 1990) as Clinical Trial, Phase IV, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2006-06-12 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-16765589-goserelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-16765589-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-16765589-goserelin-v1
- Content SHA-256: `404d684b5a5926817eba7dcb0868e26364136c7877d04e3b7f184bc600de05ef`

### Claims and source pins

#### Headline

CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93). ([`pubmed-observation-pmid-16765589-2013-11-21-30b0f94cdf8b`](#source-pubmed-observation-pmid-16765589-2013-11-21-30b0f94cdf8b))

#### Summary

PubMed lists PMID 16765589 in European journal of cancer (Oxford, England : 1990) as Clinical Trial, Phase IV, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2006-06-12 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16765589-2013-11-21-30b0f94cdf8b`](#source-pubmed-observation-pmid-16765589-2013-11-21-30b0f94cdf8b))

#### Paragraph 1

PubMed lists PMID 16765589 in European journal of cancer (Oxford, England : 1990) as Clinical Trial, Phase IV, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2006-06-12 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16765589-2013-11-21-30b0f94cdf8b`](#source-pubmed-observation-pmid-16765589-2013-11-21-30b0f94cdf8b))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-16765589-2013-11-21-30b0f94cdf8b`](#source-pubmed-observation-pmid-16765589-2013-11-21-30b0f94cdf8b))

### Sources

<a id="source-pubmed-observation-pmid-16765589-2013-11-21-30b0f94cdf8b"></a>
- **CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93). · retained source version 1:2013-11-21:current:30b0f94cdf8b77b8c8c6b10bde56fff1026d2a76f9b3f83cc02b505f2bd7be3b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/16765589/) (`pubmed-observation-pmid-16765589-2013-11-21-30b0f94cdf8b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93)." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-16765589-goserelin-v1 SHA-256: 404d684b5a5926817eba7dcb0868e26364136c7877d04e3b7f184bc600de05ef.

---

<a id="pubmed-pmid-16889194-goserelin-v1"></a>

## \[Using GnRH-agonists (Zoladex) in the treatment of genital endometriosis\].

> PubMed lists PMID 16889194 in Akusherstvo i ginekologiia as Clinical Trial, English Abstract, Journal Article, with publication-date metadata of 2006 (year precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-16889194-goserelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-16889194-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-16889194-goserelin-v1
- Content SHA-256: `2ff486aa3b3bda35bf0655cbcd20677f9f07a666ccfc9fec1875884a608e0a0b`

### Claims and source pins

#### Headline

\[Using GnRH-agonists (Zoladex) in the treatment of genital endometriosis\]. ([`pubmed-observation-pmid-16889194-2013-11-21-7506e0870b85`](#source-pubmed-observation-pmid-16889194-2013-11-21-7506e0870b85))

#### Summary

PubMed lists PMID 16889194 in Akusherstvo i ginekologiia as Clinical Trial, English Abstract, Journal Article, with publication-date metadata of 2006 (year precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16889194-2013-11-21-7506e0870b85`](#source-pubmed-observation-pmid-16889194-2013-11-21-7506e0870b85))

#### Paragraph 1

PubMed lists PMID 16889194 in Akusherstvo i ginekologiia as Clinical Trial, English Abstract, Journal Article, with publication-date metadata of 2006 (year precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16889194-2013-11-21-7506e0870b85`](#source-pubmed-observation-pmid-16889194-2013-11-21-7506e0870b85))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-16889194-2013-11-21-7506e0870b85`](#source-pubmed-observation-pmid-16889194-2013-11-21-7506e0870b85))

### Sources

<a id="source-pubmed-observation-pmid-16889194-2013-11-21-7506e0870b85"></a>
- **\[Using GnRH-agonists (Zoladex) in the treatment of genital endometriosis\]. · retained source version 1:2013-11-21:current:7506e0870b854ac1c93c1c60bff29c0b68a1c427fe0ce5e79f6f36e998701994** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/16889194/) (`pubmed-observation-pmid-16889194-2013-11-21-7506e0870b85`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Using GnRH-agonists (Zoladex) in the treatment of genital endometriosis\]." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-16889194-goserelin-v1 SHA-256: 2ff486aa3b3bda35bf0655cbcd20677f9f07a666ccfc9fec1875884a608e0a0b.

---

<a id="pubmed-pmid-17257094-goserelin-v1"></a>

## Goserelin acetate in combination with radiotherapy for prostate cancer.

> PubMed lists PMID 17257094 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2007-02 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-17257094-goserelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-09-17
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-17257094-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-17257094-goserelin-v1
- Content SHA-256: `10321c300109138447ec28d611d7602359bce97240a0df6deaad94bf4c29c821`

### Claims and source pins

#### Headline

Goserelin acetate in combination with radiotherapy for prostate cancer. ([`pubmed-observation-pmid-17257094-2019-09-17-054bef8017ae`](#source-pubmed-observation-pmid-17257094-2019-09-17-054bef8017ae))

#### Summary

PubMed lists PMID 17257094 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2007-02 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17257094-2019-09-17-054bef8017ae`](#source-pubmed-observation-pmid-17257094-2019-09-17-054bef8017ae))

#### Paragraph 1

PubMed lists PMID 17257094 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2007-02 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17257094-2019-09-17-054bef8017ae`](#source-pubmed-observation-pmid-17257094-2019-09-17-054bef8017ae))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-17257094-2019-09-17-054bef8017ae`](#source-pubmed-observation-pmid-17257094-2019-09-17-054bef8017ae))

### Sources

<a id="source-pubmed-observation-pmid-17257094-2019-09-17-054bef8017ae"></a>
- **Goserelin acetate in combination with radiotherapy for prostate cancer. · retained source version 1:2019-09-17:current:054bef8017ae042e01f3b5308d6992debf06e4d85cd1ae368bedbf6cfdc4b467** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/17257094/) (`pubmed-observation-pmid-17257094-2019-09-17-054bef8017ae`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Goserelin acetate in combination with radiotherapy for prostate cancer." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-17257094-goserelin-v1 SHA-256: 10321c300109138447ec28d611d7602359bce97240a0df6deaad94bf4c29c821.

---

<a id="pubmed-pmid-20679610-goserelin-v1"></a>

## Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women.

> PubMed lists PMID 20679610 in Journal of clinical oncology : official journal of the American Society of Clinical Oncology as Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2010-08-02 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-20679610-goserelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-03-31
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-20679610-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-20679610-goserelin-v1
- Content SHA-256: `6ea770d371a7d7e25227432e70c16b16b9be9e2bb94ac3fe78a753adb5b98c00`

### Claims and source pins

#### Headline

Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. ([`pubmed-observation-pmid-20679610-2022-03-31-593971726c44`](#source-pubmed-observation-pmid-20679610-2022-03-31-593971726c44))

#### Summary

PubMed lists PMID 20679610 in Journal of clinical oncology : official journal of the American Society of Clinical Oncology as Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2010-08-02 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20679610-2022-03-31-593971726c44`](#source-pubmed-observation-pmid-20679610-2022-03-31-593971726c44))

#### Paragraph 1

PubMed lists PMID 20679610 in Journal of clinical oncology : official journal of the American Society of Clinical Oncology as Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2010-08-02 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20679610-2022-03-31-593971726c44`](#source-pubmed-observation-pmid-20679610-2022-03-31-593971726c44))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-20679610-2022-03-31-593971726c44`](#source-pubmed-observation-pmid-20679610-2022-03-31-593971726c44))

### Sources

<a id="source-pubmed-observation-pmid-20679610-2022-03-31-593971726c44"></a>
- **Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. · retained source version 1:2022-03-31:current:593971726c444be7ed98898f746639c6da2d07def2ba1b53a9bffdd2938afb02** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/20679610/) (`pubmed-observation-pmid-20679610-2022-03-31-593971726c44`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-20679610-goserelin-v1 SHA-256: 6ea770d371a7d7e25227432e70c16b16b9be9e2bb94ac3fe78a753adb5b98c00.

---

<a id="pubmed-pmid-21380781-goserelin-v1"></a>

## A Phase II trial of Zoladex combined with CEF chemotherapy as neoadjuvant therapy in premenopausal women with hormone-responsive, operable breast cancer.

> PubMed lists PMID 21380781 in Medical oncology (Northwood, London, England) as Clinical Trial, Phase II, Journal Article, with publication-date metadata of 2011-03-06 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-21380781-goserelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-21380781-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-21380781-goserelin-v1
- Content SHA-256: `15c2cd1ff0761821cfb54e7952d656ac4d35b7a8a74b52e2ef9635b9399ce0fc`

### Claims and source pins

#### Headline

A Phase II trial of Zoladex combined with CEF chemotherapy as neoadjuvant therapy in premenopausal women with hormone-responsive, operable breast cancer. ([`pubmed-observation-pmid-21380781-2026-01-28-a60aa17e650f`](#source-pubmed-observation-pmid-21380781-2026-01-28-a60aa17e650f))

#### Summary

PubMed lists PMID 21380781 in Medical oncology (Northwood, London, England) as Clinical Trial, Phase II, Journal Article, with publication-date metadata of 2011-03-06 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-21380781-2026-01-28-a60aa17e650f`](#source-pubmed-observation-pmid-21380781-2026-01-28-a60aa17e650f))

#### Paragraph 1

PubMed lists PMID 21380781 in Medical oncology (Northwood, London, England) as Clinical Trial, Phase II, Journal Article, with publication-date metadata of 2011-03-06 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-21380781-2026-01-28-a60aa17e650f`](#source-pubmed-observation-pmid-21380781-2026-01-28-a60aa17e650f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-21380781-2026-01-28-a60aa17e650f`](#source-pubmed-observation-pmid-21380781-2026-01-28-a60aa17e650f))

### Sources

<a id="source-pubmed-observation-pmid-21380781-2026-01-28-a60aa17e650f"></a>
- **A Phase II trial of Zoladex combined with CEF chemotherapy as neoadjuvant therapy in premenopausal women with hormone-responsive, operable breast cancer. · retained source version 1:2026-01-28:current:a60aa17e650fef00e19986fb270a33164e589d667ec8d02b4ec1905a19751257** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/21380781/) (`pubmed-observation-pmid-21380781-2026-01-28-a60aa17e650f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "A Phase II trial of Zoladex combined with CEF chemotherapy as neoadjuvant therapy in premenopausal women with hormone-responsive, operable breast cancer." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-21380781-goserelin-v1 SHA-256: 15c2cd1ff0761821cfb54e7952d656ac4d35b7a8a74b52e2ef9635b9399ce0fc.

---

<a id="pubmed-pmid-21625929-goserelin-v1"></a>

## Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer.

> PubMed lists PMID 21625929 in Breast cancer research and treatment as Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2011-05-29 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-21625929-goserelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-04-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-21625929-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-21625929-goserelin-v1
- Content SHA-256: `a09d772ad83380226a6c7078aebe8f92676c472b592e82afef1b2ccf5f40b999`

### Claims and source pins

#### Headline

Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer. ([`pubmed-observation-pmid-21625929-2025-04-28-b639a6ed9cfe`](#source-pubmed-observation-pmid-21625929-2025-04-28-b639a6ed9cfe))

#### Summary

PubMed lists PMID 21625929 in Breast cancer research and treatment as Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2011-05-29 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-21625929-2025-04-28-b639a6ed9cfe`](#source-pubmed-observation-pmid-21625929-2025-04-28-b639a6ed9cfe))

#### Paragraph 1

PubMed lists PMID 21625929 in Breast cancer research and treatment as Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2011-05-29 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-21625929-2025-04-28-b639a6ed9cfe`](#source-pubmed-observation-pmid-21625929-2025-04-28-b639a6ed9cfe))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-21625929-2025-04-28-b639a6ed9cfe`](#source-pubmed-observation-pmid-21625929-2025-04-28-b639a6ed9cfe))

### Sources

<a id="source-pubmed-observation-pmid-21625929-2025-04-28-b639a6ed9cfe"></a>
- **Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer. · retained source version 1:2025-04-28:current:b639a6ed9cfe28bd523fd2aacdeb6f23559b416d3739d21e90494762608f6d76** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/21625929/) (`pubmed-observation-pmid-21625929-2025-04-28-b639a6ed9cfe`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-21625929-goserelin-v1 SHA-256: a09d772ad83380226a6c7078aebe8f92676c472b592e82afef1b2ccf5f40b999.

---

<a id="pubmed-pmid-22265697-goserelin-v1"></a>

## Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.

> PubMed lists PMID 22265697 in The Lancet. Oncology as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2012-01-20 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-22265697-goserelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-22265697-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-22265697-goserelin-v1
- Content SHA-256: `720ab3cfa23cb4a0c81b29e6e2257a9f50b9a237222e9c3626cfbbd647c7a0ab`

### Claims and source pins

#### Headline

Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. ([`pubmed-observation-pmid-22265697-2026-01-28-88b56133875b`](#source-pubmed-observation-pmid-22265697-2026-01-28-88b56133875b))

#### Summary

PubMed lists PMID 22265697 in The Lancet. Oncology as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2012-01-20 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22265697-2026-01-28-88b56133875b`](#source-pubmed-observation-pmid-22265697-2026-01-28-88b56133875b))

#### Paragraph 1

PubMed lists PMID 22265697 in The Lancet. Oncology as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2012-01-20 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22265697-2026-01-28-88b56133875b`](#source-pubmed-observation-pmid-22265697-2026-01-28-88b56133875b))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-22265697-2026-01-28-88b56133875b`](#source-pubmed-observation-pmid-22265697-2026-01-28-88b56133875b))

### Sources

<a id="source-pubmed-observation-pmid-22265697-2026-01-28-88b56133875b"></a>
- **Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. · retained source version 1:2026-01-28:current:88b56133875bb1ef7f68b2b2664a73257ac87a5079a36948f201ff04f1d67019** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/22265697/) (`pubmed-observation-pmid-22265697-2026-01-28-88b56133875b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-22265697-goserelin-v1 SHA-256: 720ab3cfa23cb4a0c81b29e6e2257a9f50b9a237222e9c3626cfbbd647c7a0ab.

---

<a id="pubmed-pmid-22674191-goserelin-v1"></a>

## Goserelin and bicalutamide treatments alter the expression of microRNAs in the prostate.

> PubMed lists PMID 22674191 in The Prostate as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2012-06-05 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-22674191-goserelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2014-11-20
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-22674191-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-22674191-goserelin-v1
- Content SHA-256: `efd4c2256985a3cab87a2f554490ade41c6393b53f94310984d9d7e9ec3bfc3c`

### Claims and source pins

#### Headline

Goserelin and bicalutamide treatments alter the expression of microRNAs in the prostate. ([`pubmed-observation-pmid-22674191-2014-11-20-fc5f2a45c0ab`](#source-pubmed-observation-pmid-22674191-2014-11-20-fc5f2a45c0ab))

#### Summary

PubMed lists PMID 22674191 in The Prostate as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2012-06-05 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22674191-2014-11-20-fc5f2a45c0ab`](#source-pubmed-observation-pmid-22674191-2014-11-20-fc5f2a45c0ab))

#### Paragraph 1

PubMed lists PMID 22674191 in The Prostate as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2012-06-05 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22674191-2014-11-20-fc5f2a45c0ab`](#source-pubmed-observation-pmid-22674191-2014-11-20-fc5f2a45c0ab))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-22674191-2014-11-20-fc5f2a45c0ab`](#source-pubmed-observation-pmid-22674191-2014-11-20-fc5f2a45c0ab))

### Sources

<a id="source-pubmed-observation-pmid-22674191-2014-11-20-fc5f2a45c0ab"></a>
- **Goserelin and bicalutamide treatments alter the expression of microRNAs in the prostate. · retained source version 1:2014-11-20:current:fc5f2a45c0abe958a0c1632f9ef7a3d9d2cff91d2ec77bc74499b5ebb351c5b1** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/22674191/) (`pubmed-observation-pmid-22674191-2014-11-20-fc5f2a45c0ab`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Goserelin and bicalutamide treatments alter the expression of microRNAs in the prostate." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-22674191-goserelin-v1 SHA-256: efd4c2256985a3cab87a2f554490ade41c6393b53f94310984d9d7e9ec3bfc3c.

---

<a id="pubmed-pmid-22972694-goserelin-v1"></a>

## Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer.

> PubMed lists PMID 22972694 in Cancer as Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2012-09-12 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-22972694-goserelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-03-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-22972694-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-22972694-goserelin-v1
- Content SHA-256: `891d4325fffc3d6bdf87b7b8745b93fe54f01c02e13613597e9666555cabf3ca`

### Claims and source pins

#### Headline

Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer. ([`pubmed-observation-pmid-22972694-2022-03-09-757f3d55dc9d`](#source-pubmed-observation-pmid-22972694-2022-03-09-757f3d55dc9d))

#### Summary

PubMed lists PMID 22972694 in Cancer as Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2012-09-12 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22972694-2022-03-09-757f3d55dc9d`](#source-pubmed-observation-pmid-22972694-2022-03-09-757f3d55dc9d))

#### Paragraph 1

PubMed lists PMID 22972694 in Cancer as Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2012-09-12 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22972694-2022-03-09-757f3d55dc9d`](#source-pubmed-observation-pmid-22972694-2022-03-09-757f3d55dc9d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-22972694-2022-03-09-757f3d55dc9d`](#source-pubmed-observation-pmid-22972694-2022-03-09-757f3d55dc9d))

### Sources

<a id="source-pubmed-observation-pmid-22972694-2022-03-09-757f3d55dc9d"></a>
- **Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer. · retained source version 1:2022-03-09:current:757f3d55dc9d72bb45cdd1e1bf1b111596b534e5dd6abaf64850537615524be2** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/22972694/) (`pubmed-observation-pmid-22972694-2022-03-09-757f3d55dc9d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-22972694-goserelin-v1 SHA-256: 891d4325fffc3d6bdf87b7b8745b93fe54f01c02e13613597e9666555cabf3ca.

---

<a id="pubmed-pmid-23184499-goserelin-v1"></a>

## Preoperative endocrine therapy with goserelin acetate and tamoxifen in hormone receptor-positive premenopausal breast cancer patients.

> PubMed lists PMID 23184499 in Breast cancer (Tokyo, Japan) as Clinical Trial, Journal Article, with publication-date metadata of 2012-11-25 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-23184499-goserelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23184499-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-23184499-goserelin-v1
- Content SHA-256: `8cfb1be24c493d347ac478aa422730af86253728cad758da3b793148f18ad68f`

### Claims and source pins

#### Headline

Preoperative endocrine therapy with goserelin acetate and tamoxifen in hormone receptor-positive premenopausal breast cancer patients. ([`pubmed-observation-pmid-23184499-2026-01-28-f3a312f08385`](#source-pubmed-observation-pmid-23184499-2026-01-28-f3a312f08385))

#### Summary

PubMed lists PMID 23184499 in Breast cancer (Tokyo, Japan) as Clinical Trial, Journal Article, with publication-date metadata of 2012-11-25 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23184499-2026-01-28-f3a312f08385`](#source-pubmed-observation-pmid-23184499-2026-01-28-f3a312f08385))

#### Paragraph 1

PubMed lists PMID 23184499 in Breast cancer (Tokyo, Japan) as Clinical Trial, Journal Article, with publication-date metadata of 2012-11-25 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23184499-2026-01-28-f3a312f08385`](#source-pubmed-observation-pmid-23184499-2026-01-28-f3a312f08385))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23184499-2026-01-28-f3a312f08385`](#source-pubmed-observation-pmid-23184499-2026-01-28-f3a312f08385))

### Sources

<a id="source-pubmed-observation-pmid-23184499-2026-01-28-f3a312f08385"></a>
- **Preoperative endocrine therapy with goserelin acetate and tamoxifen in hormone receptor-positive premenopausal breast cancer patients. · retained source version 1:2026-01-28:current:f3a312f083857450074c16fda6ee7c615d60075ad13337de2c623cfe1e04db2a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23184499/) (`pubmed-observation-pmid-23184499-2026-01-28-f3a312f08385`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Preoperative endocrine therapy with goserelin acetate and tamoxifen in hormone receptor-positive premenopausal breast cancer patients." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-23184499-goserelin-v1 SHA-256: 8cfb1be24c493d347ac478aa422730af86253728cad758da3b793148f18ad68f.

---

<a id="pubmed-pmid-26131799-goserelin-v1"></a>

## Phase II Trial of Goserelin and Exemestane Combination Therapy in Premenopausal Women With Locally Advanced or Metastatic Breast Cancer.

> PubMed lists PMID 26131799 in Medicine as Clinical Trial, Phase II, Journal Article, with publication-date metadata of 2015-07 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-26131799-goserelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-03-05
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-26131799-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-26131799-goserelin-v1
- Content SHA-256: `1190db10d278acf80803db1d4db2099d45729e6613136f6a404fe4c94578019a`

### Claims and source pins

#### Headline

Phase II Trial of Goserelin and Exemestane Combination Therapy in Premenopausal Women With Locally Advanced or Metastatic Breast Cancer. ([`pubmed-observation-pmid-26131799-2026-03-05-c69ea7ac4f01`](#source-pubmed-observation-pmid-26131799-2026-03-05-c69ea7ac4f01))

#### Summary

PubMed lists PMID 26131799 in Medicine as Clinical Trial, Phase II, Journal Article, with publication-date metadata of 2015-07 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26131799-2026-03-05-c69ea7ac4f01`](#source-pubmed-observation-pmid-26131799-2026-03-05-c69ea7ac4f01))

#### Paragraph 1

PubMed lists PMID 26131799 in Medicine as Clinical Trial, Phase II, Journal Article, with publication-date metadata of 2015-07 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26131799-2026-03-05-c69ea7ac4f01`](#source-pubmed-observation-pmid-26131799-2026-03-05-c69ea7ac4f01))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-26131799-2026-03-05-c69ea7ac4f01`](#source-pubmed-observation-pmid-26131799-2026-03-05-c69ea7ac4f01))

### Sources

<a id="source-pubmed-observation-pmid-26131799-2026-03-05-c69ea7ac4f01"></a>
- **Phase II Trial of Goserelin and Exemestane Combination Therapy in Premenopausal Women With Locally Advanced or Metastatic Breast Cancer. · retained source version 1:2026-03-05:current:c69ea7ac4f0132b023a8166d3acd70a3a238a750fa73db604f708db279db146a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/26131799/) (`pubmed-observation-pmid-26131799-2026-03-05-c69ea7ac4f01`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Phase II Trial of Goserelin and Exemestane Combination Therapy in Premenopausal Women With Locally Advanced or Metastatic Breast Cancer." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-26131799-goserelin-v1 SHA-256: 1190db10d278acf80803db1d4db2099d45729e6613136f6a404fe4c94578019a.

---

<a id="pubmed-pmid-37114900-goserelin-v1"></a>

## Erythema nodosum caused by goserelin acetate sustained-release: Case report and literature review.

> PubMed lists PMID 37114900 in International journal of rheumatic diseases as Review, Case Reports, Journal Article, with publication-date metadata of 2023-04-28 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37114900-goserelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-10-10
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37114900-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-37114900-goserelin-v1
- Content SHA-256: `6a4d5e1033f7ae524654ab26c5aaa44a9445ae3a309c8393491aca776bce08eb`

### Claims and source pins

#### Headline

Erythema nodosum caused by goserelin acetate sustained-release: Case report and literature review. ([`pubmed-observation-pmid-37114900-2023-10-10-cda527d3ead7`](#source-pubmed-observation-pmid-37114900-2023-10-10-cda527d3ead7))

#### Summary

PubMed lists PMID 37114900 in International journal of rheumatic diseases as Review, Case Reports, Journal Article, with publication-date metadata of 2023-04-28 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37114900-2023-10-10-cda527d3ead7`](#source-pubmed-observation-pmid-37114900-2023-10-10-cda527d3ead7))

#### Paragraph 1

PubMed lists PMID 37114900 in International journal of rheumatic diseases as Review, Case Reports, Journal Article, with publication-date metadata of 2023-04-28 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37114900-2023-10-10-cda527d3ead7`](#source-pubmed-observation-pmid-37114900-2023-10-10-cda527d3ead7))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37114900-2023-10-10-cda527d3ead7`](#source-pubmed-observation-pmid-37114900-2023-10-10-cda527d3ead7))

### Sources

<a id="source-pubmed-observation-pmid-37114900-2023-10-10-cda527d3ead7"></a>
- **Erythema nodosum caused by goserelin acetate sustained-release: Case report and literature review. · retained source version 1:2023-10-10:current:cda527d3ead730db258919e236d7346a9f068850f63575cbd2f53d643a0020e4** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37114900/) (`pubmed-observation-pmid-37114900-2023-10-10-cda527d3ead7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Erythema nodosum caused by goserelin acetate sustained-release: Case report and literature review." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-37114900-goserelin-v1 SHA-256: 6a4d5e1033f7ae524654ab26c5aaa44a9445ae3a309c8393491aca776bce08eb.

---

<a id="pubmed-pmid-38940667-goserelin-v1"></a>

## Apalutamide and Goserelin for Androgen Receptor-Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASU.

> PubMed lists PMID 38940667 in Clinical cancer research : an official journal of the American Association for Cancer Research as Journal Article, Clinical Trial, Phase II, Multicenter Study, with publication-date metadata of 2024-08-15 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38940667-goserelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-02-07
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38940667-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-38940667-goserelin-v1
- Content SHA-256: `7fe81257cbd2910676efaf8f2927ccd9bf55c4c83859f97fee8204753a186b8e`

### Claims and source pins

#### Headline

Apalutamide and Goserelin for Androgen Receptor-Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASU. ([`pubmed-observation-pmid-38940667-2025-02-07-3d53234f9359`](#source-pubmed-observation-pmid-38940667-2025-02-07-3d53234f9359))

#### Summary

PubMed lists PMID 38940667 in Clinical cancer research : an official journal of the American Association for Cancer Research as Journal Article, Clinical Trial, Phase II, Multicenter Study, with publication-date metadata of 2024-08-15 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38940667-2025-02-07-3d53234f9359`](#source-pubmed-observation-pmid-38940667-2025-02-07-3d53234f9359))

#### Paragraph 1

PubMed lists PMID 38940667 in Clinical cancer research : an official journal of the American Association for Cancer Research as Journal Article, Clinical Trial, Phase II, Multicenter Study, with publication-date metadata of 2024-08-15 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38940667-2025-02-07-3d53234f9359`](#source-pubmed-observation-pmid-38940667-2025-02-07-3d53234f9359))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38940667-2025-02-07-3d53234f9359`](#source-pubmed-observation-pmid-38940667-2025-02-07-3d53234f9359))

### Sources

<a id="source-pubmed-observation-pmid-38940667-2025-02-07-3d53234f9359"></a>
- **Apalutamide and Goserelin for Androgen Receptor-Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASU. · retained source version 1:2025-02-07:current:3d53234f935930a7a7a5c0614ff311abec077a8b63b94400cab362cebf21af3d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38940667/) (`pubmed-observation-pmid-38940667-2025-02-07-3d53234f9359`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Apalutamide and Goserelin for Androgen Receptor-Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASU." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-38940667-goserelin-v1 SHA-256: 7fe81257cbd2910676efaf8f2927ccd9bf55c4c83859f97fee8204753a186b8e.

---

<a id="pubmed-pmid-40268551-goserelin-v1"></a>

## \[Phase Ⅲ, multicenter, randomized comparative study of LY01005 and Zoladex® for patients with premenopausal breast cancer\].

> PubMed lists PMID 40268551 in Zhonghua zhong liu za zhi \[Chinese journal of oncology\] as Journal Article, Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase III, Comparative Study, and 1 more PubMed publication type, with publication-date metadata of 2025-04-23 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40268551-goserelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-05-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40268551-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-40268551-goserelin-v1
- Content SHA-256: `0ac574dd59a946803310b9502a881c2dc30be866cf319d05c817575459474a48`

### Claims and source pins

#### Headline

\[Phase Ⅲ, multicenter, randomized comparative study of LY01005 and Zoladex® for patients with premenopausal breast cancer\]. ([`pubmed-observation-pmid-40268551-2025-05-27-f8483e63d7d5`](#source-pubmed-observation-pmid-40268551-2025-05-27-f8483e63d7d5))

#### Summary

PubMed lists PMID 40268551 in Zhonghua zhong liu za zhi \[Chinese journal of oncology\] as Journal Article, Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase III, Comparative Study, and 1 more PubMed publication type, with publication-date metadata of 2025-04-23 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40268551-2025-05-27-f8483e63d7d5`](#source-pubmed-observation-pmid-40268551-2025-05-27-f8483e63d7d5))

#### Paragraph 1

PubMed lists PMID 40268551 in Zhonghua zhong liu za zhi \[Chinese journal of oncology\] as Journal Article, Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase III, Comparative Study, and 1 more PubMed publication type, with publication-date metadata of 2025-04-23 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40268551-2025-05-27-f8483e63d7d5`](#source-pubmed-observation-pmid-40268551-2025-05-27-f8483e63d7d5))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40268551-2025-05-27-f8483e63d7d5`](#source-pubmed-observation-pmid-40268551-2025-05-27-f8483e63d7d5))

### Sources

<a id="source-pubmed-observation-pmid-40268551-2025-05-27-f8483e63d7d5"></a>
- **\[Phase Ⅲ, multicenter, randomized comparative study of LY01005 and Zoladex® for patients with premenopausal breast cancer\]. · retained source version 1:2025-05-27:current:f8483e63d7d5b296b010c820396f61b5eed40e02791290494215faa13ec6f92c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40268551/) (`pubmed-observation-pmid-40268551-2025-05-27-f8483e63d7d5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Phase Ⅲ, multicenter, randomized comparative study of LY01005 and Zoladex® for patients with premenopausal breast cancer\]." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-40268551-goserelin-v1 SHA-256: 0ac574dd59a946803310b9502a881c2dc30be866cf319d05c817575459474a48.

---

<a id="pubmed-pmid-42226753-goserelin-v1"></a>

## Roles of Goserelin in Gynecological Disorders.

> PubMed lists PMID 42226753 in Drug design, development and therapy as Journal Article, Review, with publication-date metadata of 2026-05-27 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42226753-goserelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42226753-goserelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-42226753-goserelin-v1
- Content SHA-256: `92b50d190ba9aacd2ac0cad2c9c930495f75ea4a5a3027fcc79bf94f37172e67`

### Claims and source pins

#### Headline

Roles of Goserelin in Gynecological Disorders. ([`pubmed-observation-pmid-42226753-2026-08-13-930f5b5e431c`](#source-pubmed-observation-pmid-42226753-2026-08-13-930f5b5e431c))

#### Summary

PubMed lists PMID 42226753 in Drug design, development and therapy as Journal Article, Review, with publication-date metadata of 2026-05-27 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42226753-2026-08-13-930f5b5e431c`](#source-pubmed-observation-pmid-42226753-2026-08-13-930f5b5e431c))

#### Paragraph 1

PubMed lists PMID 42226753 in Drug design, development and therapy as Journal Article, Review, with publication-date metadata of 2026-05-27 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42226753-2026-08-13-930f5b5e431c`](#source-pubmed-observation-pmid-42226753-2026-08-13-930f5b5e431c))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42226753-2026-08-13-930f5b5e431c`](#source-pubmed-observation-pmid-42226753-2026-08-13-930f5b5e431c))

### Sources

<a id="source-pubmed-observation-pmid-42226753-2026-08-13-930f5b5e431c"></a>
- **Roles of Goserelin in Gynecological Disorders. · retained source version 1:2026-08-13:current:930f5b5e431ce260e4e55270cba34841899e2e4f507bad86e34ebb1266e9e88e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42226753/) (`pubmed-observation-pmid-42226753-2026-08-13-930f5b5e431c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Roles of Goserelin in Gynecological Disorders." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/goserelin.json#pubmed-pmid-42226753-goserelin-v1 SHA-256: 92b50d190ba9aacd2ac0cad2c9c930495f75ea4a5a3027fcc79bf94f37172e67.

